Eat slowly to reduce consumed calories

Article Type
Changed
Mon, 05/06/2019 - 12:13
Display Headline
Eat slowly to reduce consumed calories

I freely admit I am obsessed with research articles about eating habits. I hold out hope that this will eventually unlock the magic bullet to cure us of the modern plague of obesity. At a certain level, our patients need us to be captivated by such literature. We should feel fairly comfortable with the common knowledge that diets are effective if you stay on them and reducing the caloric density of foods can result in meaningful weight loss.

But what about how quickly we eat? In our fast-paced, heavily caffeinated society, we seem to shovel rather than chew. Ever since I was a medical resident, I have practically inhaled my food. Perchance I am operating under the erroneous and illogical assumption that if I don’t taste the food it won’t register as calories. True science has now enlightened me to the error in my thinking.

Dr. Jon O. Ebbert

Dr. Eric Robinson and his colleagues conducted a brilliant systematic review of the impact of eating rate on energy intake and hunger (Am. J. Clin. Nutr. 2014;100:123-51). They included studies for which there was at least one study arm in which participants ate a meal at a statistically significant slower rate than that of a different arm. Twenty-two studies met the criteria for inclusion.

Available evidence suggests that a slower eating rate is associated with lower intake, compared with faster eating. The effect on caloric intake was observed regardless of the intervention used to modify the eating rate, such as modifying food from soft (fast rate) to hard (slow rate) or verbal instruction. No relationship was observed between eating rate and hunger at the end of the meal or several hours later.

Intriguing to me is the hypothesis that eating rate likely affects intake through the duration and intensity of oral exposure to taste. Previous studies have shown that, when eating rate is held constant, increasing sensory exposure leads to a lower energy intake. This seems to relate to our innate wiring that gives us a “sensory specific satiety.” In my understanding, sensory specific satiety turns off appetitive drive when you have had too much chocolate or too many potato chips and you feel slightly ill. Unfortunately, the food industry is on to this game and they have designed foods to be perfectly balanced to not render satiety. These foods can tragically be eaten ceaselessly.

Take-home message: If your patients cannot control the bad foods they eat, they should try to eat them more slowly.

Dr. Ebbert is professor of medicine, a general internist at the Mayo Clinic in Rochester, Minn., and a diplomate of the American Board of Addiction Medicine. The opinions expressed are those of the author and do not necessarily represent the views and opinions of the Mayo Clinic. The opinions expressed in this article should not be used to diagnose or treat any medical condition nor should they be used as a substitute for medical advice from a qualified, board-certified practicing clinician.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
diet, food, calories, eating
Sections
Author and Disclosure Information

Author and Disclosure Information

I freely admit I am obsessed with research articles about eating habits. I hold out hope that this will eventually unlock the magic bullet to cure us of the modern plague of obesity. At a certain level, our patients need us to be captivated by such literature. We should feel fairly comfortable with the common knowledge that diets are effective if you stay on them and reducing the caloric density of foods can result in meaningful weight loss.

But what about how quickly we eat? In our fast-paced, heavily caffeinated society, we seem to shovel rather than chew. Ever since I was a medical resident, I have practically inhaled my food. Perchance I am operating under the erroneous and illogical assumption that if I don’t taste the food it won’t register as calories. True science has now enlightened me to the error in my thinking.

Dr. Jon O. Ebbert

Dr. Eric Robinson and his colleagues conducted a brilliant systematic review of the impact of eating rate on energy intake and hunger (Am. J. Clin. Nutr. 2014;100:123-51). They included studies for which there was at least one study arm in which participants ate a meal at a statistically significant slower rate than that of a different arm. Twenty-two studies met the criteria for inclusion.

Available evidence suggests that a slower eating rate is associated with lower intake, compared with faster eating. The effect on caloric intake was observed regardless of the intervention used to modify the eating rate, such as modifying food from soft (fast rate) to hard (slow rate) or verbal instruction. No relationship was observed between eating rate and hunger at the end of the meal or several hours later.

Intriguing to me is the hypothesis that eating rate likely affects intake through the duration and intensity of oral exposure to taste. Previous studies have shown that, when eating rate is held constant, increasing sensory exposure leads to a lower energy intake. This seems to relate to our innate wiring that gives us a “sensory specific satiety.” In my understanding, sensory specific satiety turns off appetitive drive when you have had too much chocolate or too many potato chips and you feel slightly ill. Unfortunately, the food industry is on to this game and they have designed foods to be perfectly balanced to not render satiety. These foods can tragically be eaten ceaselessly.

Take-home message: If your patients cannot control the bad foods they eat, they should try to eat them more slowly.

Dr. Ebbert is professor of medicine, a general internist at the Mayo Clinic in Rochester, Minn., and a diplomate of the American Board of Addiction Medicine. The opinions expressed are those of the author and do not necessarily represent the views and opinions of the Mayo Clinic. The opinions expressed in this article should not be used to diagnose or treat any medical condition nor should they be used as a substitute for medical advice from a qualified, board-certified practicing clinician.

I freely admit I am obsessed with research articles about eating habits. I hold out hope that this will eventually unlock the magic bullet to cure us of the modern plague of obesity. At a certain level, our patients need us to be captivated by such literature. We should feel fairly comfortable with the common knowledge that diets are effective if you stay on them and reducing the caloric density of foods can result in meaningful weight loss.

But what about how quickly we eat? In our fast-paced, heavily caffeinated society, we seem to shovel rather than chew. Ever since I was a medical resident, I have practically inhaled my food. Perchance I am operating under the erroneous and illogical assumption that if I don’t taste the food it won’t register as calories. True science has now enlightened me to the error in my thinking.

Dr. Jon O. Ebbert

Dr. Eric Robinson and his colleagues conducted a brilliant systematic review of the impact of eating rate on energy intake and hunger (Am. J. Clin. Nutr. 2014;100:123-51). They included studies for which there was at least one study arm in which participants ate a meal at a statistically significant slower rate than that of a different arm. Twenty-two studies met the criteria for inclusion.

Available evidence suggests that a slower eating rate is associated with lower intake, compared with faster eating. The effect on caloric intake was observed regardless of the intervention used to modify the eating rate, such as modifying food from soft (fast rate) to hard (slow rate) or verbal instruction. No relationship was observed between eating rate and hunger at the end of the meal or several hours later.

Intriguing to me is the hypothesis that eating rate likely affects intake through the duration and intensity of oral exposure to taste. Previous studies have shown that, when eating rate is held constant, increasing sensory exposure leads to a lower energy intake. This seems to relate to our innate wiring that gives us a “sensory specific satiety.” In my understanding, sensory specific satiety turns off appetitive drive when you have had too much chocolate or too many potato chips and you feel slightly ill. Unfortunately, the food industry is on to this game and they have designed foods to be perfectly balanced to not render satiety. These foods can tragically be eaten ceaselessly.

Take-home message: If your patients cannot control the bad foods they eat, they should try to eat them more slowly.

Dr. Ebbert is professor of medicine, a general internist at the Mayo Clinic in Rochester, Minn., and a diplomate of the American Board of Addiction Medicine. The opinions expressed are those of the author and do not necessarily represent the views and opinions of the Mayo Clinic. The opinions expressed in this article should not be used to diagnose or treat any medical condition nor should they be used as a substitute for medical advice from a qualified, board-certified practicing clinician.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Eat slowly to reduce consumed calories
Display Headline
Eat slowly to reduce consumed calories
Legacy Keywords
diet, food, calories, eating
Legacy Keywords
diet, food, calories, eating
Sections
Article Source

PURLs Copyright

Inside the Article

Physician Advocacy for Zoster Vaccination

Article Type
Changed
Thu, 01/10/2019 - 13:22
Display Headline
Physician Advocacy for Zoster Vaccination

Herpes zoster (HZ) infection occurs when the varicella-zoster virus (VZV) is reactivated due to waning cellular immunity associated with age or immunosuppression. It results in a painful blistering cutaneous eruption.1 The incidence and rate of complications from HZ infection increase with age.2 The most common complication of HZ infection is postherpetic neuralgia (PHN), which can be extremely debilitating.1

In 2006 the US Food and Drug Administration approved a live attenuated HZ vaccine that boosts VZV cell-mediated immunity and largely reduces HZ disease burden. The HZ vaccine contains the same strain of VZV as the varicella vaccine but contains 14 times more virus particles.3 In a study of the efficacy and safety of the HZ vaccine, HZ vaccination was associated with a 51% reduction in HZ incidence, a 61% reduction in HZ disease burden, and a 67% reduction in PHN incidence at 3-year follow-up.4 In adults aged 60 to 69 years, the benefit of the HZ vaccine resulted from the reduction in HZ incidence.5 However, in adults 70 years and older, the benefit resulted from the reduction in PHN incidence and severity. Overall, the absolute benefit of the HZ vaccine was greatest in the older age group, as the severity and incidence of HZ and PHN are highest in these patients.5 Although efficacy declines with time, a long-term persistence substudy demonstrated that the HZ vaccine still reduced the incidence and severity of HZ.6

The HZ vaccine currently is approved for adults aged 50 years or older.3 Antivirals that are active against VZV (eg, acyclovir, valacyclovir, famciclovir) should not be administered 24 hours before or 14 days after vaccination.1 Concurrent administration of the HZ vaccine and the pneumococcal vaccine is not recommended due to risk for reduced immunogenicity of the zoster vaccine.5 Because it is a live vaccine, the HZ vaccine is not recommended in immunocompromised patients. However, the HZ vaccine can be safely given to moderately immunosuppressed patients. The HZ vaccine also is well tolerated and stimulates a strong cell-mediated immune response in adults who have had prior HZ infections. Herpes zoster vaccination is recommended in patients with a history of shingles, though there are no published data showing that it reduces the already low rate of recurrent HZ infections.7

Despite strong efficacy data and established guidelines, a low vaccination rate has been reported8 due to doubts about its long-term efficacy, failure of both physicians and patients to recognize the burden of disease imposed by HZ infection and PHN, and concerns about reimbursement and out-of-pocket costs for the patient.5 Furthermore, many patients who are eligible to receive the HZ vaccine may not do so because they do not remember having chickenpox and therefore do not feel they are at risk for developing shingles.

The HZ vaccine is an important factor in public health prevention strategy, as HZ infection and PHN are common, incurable, and incapacitating. The HZ vaccine is the most efficacious agent currently available on the market for prevention. It is important for dermatologists to educate our patients and encourage them to receive the HZ vaccine to safeguard their long-term health.

References

1. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274-280.

2. Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269:496-506.

3. Javed S, Javed SA, Trying SK. Varicella vaccines. Curr Open Infect Dis. 2012;25:135-140.

4. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;353:2271-2284.

5. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197-213.

6. Keating GM. Shingles (herpes zoster) vaccine (Zostavax®): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged >50 years. Drugs. 2013;73:1227-1244.

7. Herpes zoster vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Updated March 12, 2015. Accessed April 21, 2015.

8. Langan SM, Smeeth L, Margolis D, et al. Herpes zoster vaccine effectiveness against herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420.

Article PDF
Author and Disclosure Information

Ramya Kollipara, MD; Stephen K. Tyring, MD, PhD

Both from the Center for Clinical Studies, Houston, Texas. Dr. Tyring also is from the Department of Dermatology, University of Texas Health Science Center at Houston.

Dr. Kollipara reports no conflict of interest. Dr. Tyring reports that Merck & Co has sponsored vaccine studies in his clinic.

Correspondence: Ramya Kollipara, MD, 20320 Northwest Fwy, Ste 700, Houston, TX 77065 ([email protected]).

Issue
Cutis - 95(5)
Publications
Topics
Page Number
251
Legacy Keywords
Herpes zoster, herpes zoster infection, HZ, varicella-zoster virus, VZV, HZ vaccine
Sections
Author and Disclosure Information

Ramya Kollipara, MD; Stephen K. Tyring, MD, PhD

Both from the Center for Clinical Studies, Houston, Texas. Dr. Tyring also is from the Department of Dermatology, University of Texas Health Science Center at Houston.

Dr. Kollipara reports no conflict of interest. Dr. Tyring reports that Merck & Co has sponsored vaccine studies in his clinic.

Correspondence: Ramya Kollipara, MD, 20320 Northwest Fwy, Ste 700, Houston, TX 77065 ([email protected]).

Author and Disclosure Information

Ramya Kollipara, MD; Stephen K. Tyring, MD, PhD

Both from the Center for Clinical Studies, Houston, Texas. Dr. Tyring also is from the Department of Dermatology, University of Texas Health Science Center at Houston.

Dr. Kollipara reports no conflict of interest. Dr. Tyring reports that Merck & Co has sponsored vaccine studies in his clinic.

Correspondence: Ramya Kollipara, MD, 20320 Northwest Fwy, Ste 700, Houston, TX 77065 ([email protected]).

Article PDF
Article PDF
Related Articles

Herpes zoster (HZ) infection occurs when the varicella-zoster virus (VZV) is reactivated due to waning cellular immunity associated with age or immunosuppression. It results in a painful blistering cutaneous eruption.1 The incidence and rate of complications from HZ infection increase with age.2 The most common complication of HZ infection is postherpetic neuralgia (PHN), which can be extremely debilitating.1

In 2006 the US Food and Drug Administration approved a live attenuated HZ vaccine that boosts VZV cell-mediated immunity and largely reduces HZ disease burden. The HZ vaccine contains the same strain of VZV as the varicella vaccine but contains 14 times more virus particles.3 In a study of the efficacy and safety of the HZ vaccine, HZ vaccination was associated with a 51% reduction in HZ incidence, a 61% reduction in HZ disease burden, and a 67% reduction in PHN incidence at 3-year follow-up.4 In adults aged 60 to 69 years, the benefit of the HZ vaccine resulted from the reduction in HZ incidence.5 However, in adults 70 years and older, the benefit resulted from the reduction in PHN incidence and severity. Overall, the absolute benefit of the HZ vaccine was greatest in the older age group, as the severity and incidence of HZ and PHN are highest in these patients.5 Although efficacy declines with time, a long-term persistence substudy demonstrated that the HZ vaccine still reduced the incidence and severity of HZ.6

The HZ vaccine currently is approved for adults aged 50 years or older.3 Antivirals that are active against VZV (eg, acyclovir, valacyclovir, famciclovir) should not be administered 24 hours before or 14 days after vaccination.1 Concurrent administration of the HZ vaccine and the pneumococcal vaccine is not recommended due to risk for reduced immunogenicity of the zoster vaccine.5 Because it is a live vaccine, the HZ vaccine is not recommended in immunocompromised patients. However, the HZ vaccine can be safely given to moderately immunosuppressed patients. The HZ vaccine also is well tolerated and stimulates a strong cell-mediated immune response in adults who have had prior HZ infections. Herpes zoster vaccination is recommended in patients with a history of shingles, though there are no published data showing that it reduces the already low rate of recurrent HZ infections.7

Despite strong efficacy data and established guidelines, a low vaccination rate has been reported8 due to doubts about its long-term efficacy, failure of both physicians and patients to recognize the burden of disease imposed by HZ infection and PHN, and concerns about reimbursement and out-of-pocket costs for the patient.5 Furthermore, many patients who are eligible to receive the HZ vaccine may not do so because they do not remember having chickenpox and therefore do not feel they are at risk for developing shingles.

The HZ vaccine is an important factor in public health prevention strategy, as HZ infection and PHN are common, incurable, and incapacitating. The HZ vaccine is the most efficacious agent currently available on the market for prevention. It is important for dermatologists to educate our patients and encourage them to receive the HZ vaccine to safeguard their long-term health.

Herpes zoster (HZ) infection occurs when the varicella-zoster virus (VZV) is reactivated due to waning cellular immunity associated with age or immunosuppression. It results in a painful blistering cutaneous eruption.1 The incidence and rate of complications from HZ infection increase with age.2 The most common complication of HZ infection is postherpetic neuralgia (PHN), which can be extremely debilitating.1

In 2006 the US Food and Drug Administration approved a live attenuated HZ vaccine that boosts VZV cell-mediated immunity and largely reduces HZ disease burden. The HZ vaccine contains the same strain of VZV as the varicella vaccine but contains 14 times more virus particles.3 In a study of the efficacy and safety of the HZ vaccine, HZ vaccination was associated with a 51% reduction in HZ incidence, a 61% reduction in HZ disease burden, and a 67% reduction in PHN incidence at 3-year follow-up.4 In adults aged 60 to 69 years, the benefit of the HZ vaccine resulted from the reduction in HZ incidence.5 However, in adults 70 years and older, the benefit resulted from the reduction in PHN incidence and severity. Overall, the absolute benefit of the HZ vaccine was greatest in the older age group, as the severity and incidence of HZ and PHN are highest in these patients.5 Although efficacy declines with time, a long-term persistence substudy demonstrated that the HZ vaccine still reduced the incidence and severity of HZ.6

The HZ vaccine currently is approved for adults aged 50 years or older.3 Antivirals that are active against VZV (eg, acyclovir, valacyclovir, famciclovir) should not be administered 24 hours before or 14 days after vaccination.1 Concurrent administration of the HZ vaccine and the pneumococcal vaccine is not recommended due to risk for reduced immunogenicity of the zoster vaccine.5 Because it is a live vaccine, the HZ vaccine is not recommended in immunocompromised patients. However, the HZ vaccine can be safely given to moderately immunosuppressed patients. The HZ vaccine also is well tolerated and stimulates a strong cell-mediated immune response in adults who have had prior HZ infections. Herpes zoster vaccination is recommended in patients with a history of shingles, though there are no published data showing that it reduces the already low rate of recurrent HZ infections.7

Despite strong efficacy data and established guidelines, a low vaccination rate has been reported8 due to doubts about its long-term efficacy, failure of both physicians and patients to recognize the burden of disease imposed by HZ infection and PHN, and concerns about reimbursement and out-of-pocket costs for the patient.5 Furthermore, many patients who are eligible to receive the HZ vaccine may not do so because they do not remember having chickenpox and therefore do not feel they are at risk for developing shingles.

The HZ vaccine is an important factor in public health prevention strategy, as HZ infection and PHN are common, incurable, and incapacitating. The HZ vaccine is the most efficacious agent currently available on the market for prevention. It is important for dermatologists to educate our patients and encourage them to receive the HZ vaccine to safeguard their long-term health.

References

1. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274-280.

2. Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269:496-506.

3. Javed S, Javed SA, Trying SK. Varicella vaccines. Curr Open Infect Dis. 2012;25:135-140.

4. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;353:2271-2284.

5. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197-213.

6. Keating GM. Shingles (herpes zoster) vaccine (Zostavax®): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged >50 years. Drugs. 2013;73:1227-1244.

7. Herpes zoster vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Updated March 12, 2015. Accessed April 21, 2015.

8. Langan SM, Smeeth L, Margolis D, et al. Herpes zoster vaccine effectiveness against herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420.

References

1. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274-280.

2. Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269:496-506.

3. Javed S, Javed SA, Trying SK. Varicella vaccines. Curr Open Infect Dis. 2012;25:135-140.

4. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;353:2271-2284.

5. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197-213.

6. Keating GM. Shingles (herpes zoster) vaccine (Zostavax®): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged >50 years. Drugs. 2013;73:1227-1244.

7. Herpes zoster vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Updated March 12, 2015. Accessed April 21, 2015.

8. Langan SM, Smeeth L, Margolis D, et al. Herpes zoster vaccine effectiveness against herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420.

Issue
Cutis - 95(5)
Issue
Cutis - 95(5)
Page Number
251
Page Number
251
Publications
Publications
Topics
Article Type
Display Headline
Physician Advocacy for Zoster Vaccination
Display Headline
Physician Advocacy for Zoster Vaccination
Legacy Keywords
Herpes zoster, herpes zoster infection, HZ, varicella-zoster virus, VZV, HZ vaccine
Legacy Keywords
Herpes zoster, herpes zoster infection, HZ, varicella-zoster virus, VZV, HZ vaccine
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Trauma center verification

Article Type
Changed
Wed, 01/02/2019 - 09:13
Display Headline
Trauma center verification

Despite the many changes in medicine over the past century, traumatic injury remains a surgical disease.

Trauma injury is a major public health concern in rural areas, where death rates from unintentional injuries are higher than in metropolitan areas (Am. J. Public Health 2004;10:1689-93). The rural surgeon sees more than his or her fair share of victims of automobile accidents, falls, unintentional firearms injuries, and occupational accidents (think tractor accidents and injuries involving machinery and animals).

Dr. Philip R. Caropreso

Another reality of the rural areas of the United States is that the number of broadly trained general surgeons who can treat a wide variety of trauma injuries is shrinking. Aging and retirements of the “old school rural surgeons” are accelerating and precipitating a lack of surgical coverage crisis, including trauma, in rural areas (Arch. Surg. 2005;140:74-9).

These well-documented developments have combined to reduce the availability of rural surgeons to manage injured patients in planned and consistent ways. Because of the current training paradigm of increasing subspecialization, injured rural patients may be cared for at rural hospitals with reduced capabilities and by rural surgeons with limited trauma training and experience.

What is the action plan to help counteract these developments and to provide the highest-quality patient care at facilities staffed by surgeons who have sworn to “serve all with skill and fidelity”?

The most straightforward and well-established action plan to achieve those goals is the verification process developed by the ACS Verification, Review, and Consultation Program (VRC) in 1987 to help hospitals improve trauma care. The process involves a pre-review questionnaire, a site visit, and report of findings. Verification as a trauma center guarantees that the facility has the required resources listed in the current, evidence-based guide, Resources for Optimal Care of the Injured Patient (2014). If successful, the trauma center receives a certificate of verification that is valid for 3 years.

Most rural hospitals are designated as Level III and IV verified trauma centers on the basis of their available resources. ACS verification confirms that these centers have the commitments and capabilities to manage the initial care of injured patients by providing stabilization and instituting life-saving maneuvers. In addition, verification confirms that protocols and agreements with higher-level trauma centers within a system enable the safe and efficient transfer of injured patients.

During many years of practice in the rural hospitals verified as trauma centers, including being the medical director of a Level II and Level III facility, I provided care to injured patients who presented to the emergency departments (EDs). My experiences confirmed the unequivocal value of practicing in those facilities, and I can attest to the benefits of verification within a system, like Iowa’s state program.

The following case report validates such assertions. A helicopter, unable to complete the transfer to a Level I center for a deteriorating patient with a left chest gunshot wound, landed at my Level III hospital. There was a “Hot Off Load,” which was followed by a full trauma alert for the patient in profound shock. After placing a chest tube during a 20-minute ED stay, the patient transferred to the OR for further resuscitation, and stabilization with required operative treatment. With the patient stabilized and fully resuscitated, according to established agreements, I contacted the Level I center from the OR. After 3 hours, the patient returned to the helicopter and completed the transfer to the Level I trauma center. The patient survived because of the local trauma team’s commitment, organization, and skill brought about by the trauma center verification.

Most research to date has focused on higher-level trauma centers, but recent studies have shown that ACS verification was an independent predictor of survival of trauma patients at Level II centers (J. Trauma Acute Care Surg. 2013;75:44-9; J. Trauma Acute Care Surg. 2010;69:1362-6).

I have firsthand experience with the verification process. Following my involvement with the ACS Committee on Trauma, I became a national site surveyor for the ACSVRC. I became an Advanced Trauma Life Support (ATLS) instructor and then worked as a course director. ATLS is an essential component for trauma center verification. It supports the rural surgeon by giving the local trauma team a format for consistent, life-saving care for the most severely injured patients. I subsequently completed the ACS Advanced Trauma Operative Management course and elected to become an instructor.

I have made site visits to many rural hospitals as a part of the ACSVRC process and have met with a wide range of reactions from “Let’s show off how good we are” to “We really don’t know why we’re doing this” to “Just give us the merit badge and then get out of our hair.” I am gratified to note that ACS Fellows are uniformly supportive. They understand the need for organization, standards, and performance improvement.

 

 

Opposition to the ACSVRC process by hospitals and staff is no doubt rooted in cost concerns and general resistance to change. But, as most of us know, demonstrated benefits for patient care can be highly persuasive to most medical professionals.

It is also worth noting that in an effort to decrease stress, the ACSVRC takes significant steps to support facilities that seek verification by eliminating ambiguity from application to on-site visit, by defining criteria deficiencies, and by providing evidence for the entire verification process. The complete VRC program along with an FAQ is available on the ACS website (facs.org/quality-programs/trauma/vrc).

For me, trauma care has always been about what is best for the injured patient. I often ask colleagues this question: “What care do you want for an injured member of your family?” I then answer my own question: “I want the best care possible. That means organized, efficient, and life-saving [care] if needed.” Fortunately, I experienced these benefits at my verified trauma center hospital when my second son was in a rollover motor vehicle crash. He survived.

Verified rural trauma centers do indeed offer the best opportunities for high-quality patient care and for support of the rural surgeons who render that care to “serve all with skill and fidelity.” I know. I have been there.

Dr. Caropreso is a general surgeon at Keokuk (Iowa) Area Hospital and clinical professor of surgery at the University of Iowa Carver College of Medicine, Iowa City. He has practiced surgery in the rural communities of Mason City, Iowa; Keokuk, Iowa; and Carthage, Ill., for 37 years.

References

Author and Disclosure Information

Publications
Sections
Author and Disclosure Information

Author and Disclosure Information

Despite the many changes in medicine over the past century, traumatic injury remains a surgical disease.

Trauma injury is a major public health concern in rural areas, where death rates from unintentional injuries are higher than in metropolitan areas (Am. J. Public Health 2004;10:1689-93). The rural surgeon sees more than his or her fair share of victims of automobile accidents, falls, unintentional firearms injuries, and occupational accidents (think tractor accidents and injuries involving machinery and animals).

Dr. Philip R. Caropreso

Another reality of the rural areas of the United States is that the number of broadly trained general surgeons who can treat a wide variety of trauma injuries is shrinking. Aging and retirements of the “old school rural surgeons” are accelerating and precipitating a lack of surgical coverage crisis, including trauma, in rural areas (Arch. Surg. 2005;140:74-9).

These well-documented developments have combined to reduce the availability of rural surgeons to manage injured patients in planned and consistent ways. Because of the current training paradigm of increasing subspecialization, injured rural patients may be cared for at rural hospitals with reduced capabilities and by rural surgeons with limited trauma training and experience.

What is the action plan to help counteract these developments and to provide the highest-quality patient care at facilities staffed by surgeons who have sworn to “serve all with skill and fidelity”?

The most straightforward and well-established action plan to achieve those goals is the verification process developed by the ACS Verification, Review, and Consultation Program (VRC) in 1987 to help hospitals improve trauma care. The process involves a pre-review questionnaire, a site visit, and report of findings. Verification as a trauma center guarantees that the facility has the required resources listed in the current, evidence-based guide, Resources for Optimal Care of the Injured Patient (2014). If successful, the trauma center receives a certificate of verification that is valid for 3 years.

Most rural hospitals are designated as Level III and IV verified trauma centers on the basis of their available resources. ACS verification confirms that these centers have the commitments and capabilities to manage the initial care of injured patients by providing stabilization and instituting life-saving maneuvers. In addition, verification confirms that protocols and agreements with higher-level trauma centers within a system enable the safe and efficient transfer of injured patients.

During many years of practice in the rural hospitals verified as trauma centers, including being the medical director of a Level II and Level III facility, I provided care to injured patients who presented to the emergency departments (EDs). My experiences confirmed the unequivocal value of practicing in those facilities, and I can attest to the benefits of verification within a system, like Iowa’s state program.

The following case report validates such assertions. A helicopter, unable to complete the transfer to a Level I center for a deteriorating patient with a left chest gunshot wound, landed at my Level III hospital. There was a “Hot Off Load,” which was followed by a full trauma alert for the patient in profound shock. After placing a chest tube during a 20-minute ED stay, the patient transferred to the OR for further resuscitation, and stabilization with required operative treatment. With the patient stabilized and fully resuscitated, according to established agreements, I contacted the Level I center from the OR. After 3 hours, the patient returned to the helicopter and completed the transfer to the Level I trauma center. The patient survived because of the local trauma team’s commitment, organization, and skill brought about by the trauma center verification.

Most research to date has focused on higher-level trauma centers, but recent studies have shown that ACS verification was an independent predictor of survival of trauma patients at Level II centers (J. Trauma Acute Care Surg. 2013;75:44-9; J. Trauma Acute Care Surg. 2010;69:1362-6).

I have firsthand experience with the verification process. Following my involvement with the ACS Committee on Trauma, I became a national site surveyor for the ACSVRC. I became an Advanced Trauma Life Support (ATLS) instructor and then worked as a course director. ATLS is an essential component for trauma center verification. It supports the rural surgeon by giving the local trauma team a format for consistent, life-saving care for the most severely injured patients. I subsequently completed the ACS Advanced Trauma Operative Management course and elected to become an instructor.

I have made site visits to many rural hospitals as a part of the ACSVRC process and have met with a wide range of reactions from “Let’s show off how good we are” to “We really don’t know why we’re doing this” to “Just give us the merit badge and then get out of our hair.” I am gratified to note that ACS Fellows are uniformly supportive. They understand the need for organization, standards, and performance improvement.

 

 

Opposition to the ACSVRC process by hospitals and staff is no doubt rooted in cost concerns and general resistance to change. But, as most of us know, demonstrated benefits for patient care can be highly persuasive to most medical professionals.

It is also worth noting that in an effort to decrease stress, the ACSVRC takes significant steps to support facilities that seek verification by eliminating ambiguity from application to on-site visit, by defining criteria deficiencies, and by providing evidence for the entire verification process. The complete VRC program along with an FAQ is available on the ACS website (facs.org/quality-programs/trauma/vrc).

For me, trauma care has always been about what is best for the injured patient. I often ask colleagues this question: “What care do you want for an injured member of your family?” I then answer my own question: “I want the best care possible. That means organized, efficient, and life-saving [care] if needed.” Fortunately, I experienced these benefits at my verified trauma center hospital when my second son was in a rollover motor vehicle crash. He survived.

Verified rural trauma centers do indeed offer the best opportunities for high-quality patient care and for support of the rural surgeons who render that care to “serve all with skill and fidelity.” I know. I have been there.

Dr. Caropreso is a general surgeon at Keokuk (Iowa) Area Hospital and clinical professor of surgery at the University of Iowa Carver College of Medicine, Iowa City. He has practiced surgery in the rural communities of Mason City, Iowa; Keokuk, Iowa; and Carthage, Ill., for 37 years.

Despite the many changes in medicine over the past century, traumatic injury remains a surgical disease.

Trauma injury is a major public health concern in rural areas, where death rates from unintentional injuries are higher than in metropolitan areas (Am. J. Public Health 2004;10:1689-93). The rural surgeon sees more than his or her fair share of victims of automobile accidents, falls, unintentional firearms injuries, and occupational accidents (think tractor accidents and injuries involving machinery and animals).

Dr. Philip R. Caropreso

Another reality of the rural areas of the United States is that the number of broadly trained general surgeons who can treat a wide variety of trauma injuries is shrinking. Aging and retirements of the “old school rural surgeons” are accelerating and precipitating a lack of surgical coverage crisis, including trauma, in rural areas (Arch. Surg. 2005;140:74-9).

These well-documented developments have combined to reduce the availability of rural surgeons to manage injured patients in planned and consistent ways. Because of the current training paradigm of increasing subspecialization, injured rural patients may be cared for at rural hospitals with reduced capabilities and by rural surgeons with limited trauma training and experience.

What is the action plan to help counteract these developments and to provide the highest-quality patient care at facilities staffed by surgeons who have sworn to “serve all with skill and fidelity”?

The most straightforward and well-established action plan to achieve those goals is the verification process developed by the ACS Verification, Review, and Consultation Program (VRC) in 1987 to help hospitals improve trauma care. The process involves a pre-review questionnaire, a site visit, and report of findings. Verification as a trauma center guarantees that the facility has the required resources listed in the current, evidence-based guide, Resources for Optimal Care of the Injured Patient (2014). If successful, the trauma center receives a certificate of verification that is valid for 3 years.

Most rural hospitals are designated as Level III and IV verified trauma centers on the basis of their available resources. ACS verification confirms that these centers have the commitments and capabilities to manage the initial care of injured patients by providing stabilization and instituting life-saving maneuvers. In addition, verification confirms that protocols and agreements with higher-level trauma centers within a system enable the safe and efficient transfer of injured patients.

During many years of practice in the rural hospitals verified as trauma centers, including being the medical director of a Level II and Level III facility, I provided care to injured patients who presented to the emergency departments (EDs). My experiences confirmed the unequivocal value of practicing in those facilities, and I can attest to the benefits of verification within a system, like Iowa’s state program.

The following case report validates such assertions. A helicopter, unable to complete the transfer to a Level I center for a deteriorating patient with a left chest gunshot wound, landed at my Level III hospital. There was a “Hot Off Load,” which was followed by a full trauma alert for the patient in profound shock. After placing a chest tube during a 20-minute ED stay, the patient transferred to the OR for further resuscitation, and stabilization with required operative treatment. With the patient stabilized and fully resuscitated, according to established agreements, I contacted the Level I center from the OR. After 3 hours, the patient returned to the helicopter and completed the transfer to the Level I trauma center. The patient survived because of the local trauma team’s commitment, organization, and skill brought about by the trauma center verification.

Most research to date has focused on higher-level trauma centers, but recent studies have shown that ACS verification was an independent predictor of survival of trauma patients at Level II centers (J. Trauma Acute Care Surg. 2013;75:44-9; J. Trauma Acute Care Surg. 2010;69:1362-6).

I have firsthand experience with the verification process. Following my involvement with the ACS Committee on Trauma, I became a national site surveyor for the ACSVRC. I became an Advanced Trauma Life Support (ATLS) instructor and then worked as a course director. ATLS is an essential component for trauma center verification. It supports the rural surgeon by giving the local trauma team a format for consistent, life-saving care for the most severely injured patients. I subsequently completed the ACS Advanced Trauma Operative Management course and elected to become an instructor.

I have made site visits to many rural hospitals as a part of the ACSVRC process and have met with a wide range of reactions from “Let’s show off how good we are” to “We really don’t know why we’re doing this” to “Just give us the merit badge and then get out of our hair.” I am gratified to note that ACS Fellows are uniformly supportive. They understand the need for organization, standards, and performance improvement.

 

 

Opposition to the ACSVRC process by hospitals and staff is no doubt rooted in cost concerns and general resistance to change. But, as most of us know, demonstrated benefits for patient care can be highly persuasive to most medical professionals.

It is also worth noting that in an effort to decrease stress, the ACSVRC takes significant steps to support facilities that seek verification by eliminating ambiguity from application to on-site visit, by defining criteria deficiencies, and by providing evidence for the entire verification process. The complete VRC program along with an FAQ is available on the ACS website (facs.org/quality-programs/trauma/vrc).

For me, trauma care has always been about what is best for the injured patient. I often ask colleagues this question: “What care do you want for an injured member of your family?” I then answer my own question: “I want the best care possible. That means organized, efficient, and life-saving [care] if needed.” Fortunately, I experienced these benefits at my verified trauma center hospital when my second son was in a rollover motor vehicle crash. He survived.

Verified rural trauma centers do indeed offer the best opportunities for high-quality patient care and for support of the rural surgeons who render that care to “serve all with skill and fidelity.” I know. I have been there.

Dr. Caropreso is a general surgeon at Keokuk (Iowa) Area Hospital and clinical professor of surgery at the University of Iowa Carver College of Medicine, Iowa City. He has practiced surgery in the rural communities of Mason City, Iowa; Keokuk, Iowa; and Carthage, Ill., for 37 years.

References

References

Publications
Publications
Article Type
Display Headline
Trauma center verification
Display Headline
Trauma center verification
Sections
Article Source

PURLs Copyright

Inside the Article

From the Washington Office

Article Type
Changed
Wed, 01/02/2019 - 09:13
Display Headline
From the Washington Office

S…G…R (continued) – It is much to all of our collective delight and relief that the SGR has finally been relegated to the ash heap of history.

In the late evening of April 14, in an act of historic bipartisanship, the Senate voted 92-8 in favor of H.R. 2 thus completing legislative action about which I wrote last month. President Obama signed the bill into law on April 16. As I write, Dave Hoyt, ACS Executive Director, is attending an event at the White House, along with other leaders of the physician community, to celebrate the full and permanent repeal of the SGR.

Dr. Patrick V. Bailey, FACS

In the coming months, I will use this column to inform surgeons about various components of the legislation and its attendant policy. To start this process, I would first like to cover the key provisions of what is now known as MACRA – the Medicare Access and CHIP Reauthorization Act.

For starters, MACRA fully and permanently repeals the sustainable growth rate (SGR), thus providing stability to the Medicare physician fee schedule. Such repeal averts a 21% SGR-induced cut scheduled for April 1, 2015. MACRA also provides modest but stable positive updates of 0.5%/year for 5 years. When the legislative template that ultimately became MACRA was negotiated in late 2013 and early 2014, no provision was initially made for a positive update to physician payment. However, as a direct result of objections made by the leadership of the ACS, the legislation was subsequently revised to include the 0.5%/year update.

In addition, MACRA provides for the elimination, in 2018, of the current-law penalties associated with the existing quality programs, namely the Physician Quality Reporting System (PQRS), the Value-Based Modifier (VBM) program, and the Electronic Health Record-Meaningful Use (EHR-MU) program. The monies expected from those penalties will be returned to the pool, thus increasing the amount of funds available for incentive updates.

Beginning in 2019, these three programs will be combined into a single program known as the Merit-Based Incentive Payment System (MIPS). The MIPS makes it possible for all surgeons to receive an annual positive update based on their individual performance in four categories of Quality, Resource Use, Meaningful use of the electronic health record, and Clinical practice improvement activities. Surgeons will receive an annual, individual, single composite score based on their performance in these four categories. This score will be compared to a threshold score, defined as either the mean or median of composite scores from a prior performance period. Those with a score above the threshold will receive a positive adjustment and those with a score below the threshold will receive a negative adjustment.The legislation also provides the opportunity to receive a 5% bonus beginning in 2019 for participation in an Alternative Payment Model (APM). Surgeons who meet the full APM criteria will also be excluded from the MIPS assessment and most EHR-MU requirements. Those who participate in an APM at lower levels will receive credit toward their MIPS score. The bonus payment encourages the development of, testing of, and participation in an alternative payment model.

The passage of MACRA also represents a major victory relative to the College’s efforts to rescind the CMS policy transitioning 10- and 90-day global codes to zero-day global codes. ACS leadership and staff of the D.C. office had direct input into the specific language included in the legislation through multiple exchanges with congressional committee staff. In short, MACRA prohibits CMS from implementing its flawed plan relative to the transitioning of the global codes. Instead, beginning no later than 2017, CMS will collect samples of data on the number and level of postoperative visits furnished during the global period. Beginning in 2019, CMS will use this data to improve the accuracy of the valuation of surgical services. CMS is allowed to withhold 5% of the surgical payment until the sample information is reported at the end of the global period.

While MACRA does not implement broad medical liability reforms, it does include a provision which assures that MIPS participation cannot be used in a medical liability action. Specifically, the legislation specifies that the development, recognition or implementation of any guideline or other standard under any federal health care provision, including Medicare, cannot be construed as to establish the standard of care or duty of care owed by a surgeon to a patient in any medical malpractice claim.

Finally, and of particular interest to pediatric surgeons and other surgeons who care for children, MACRA includes two years of additional funding for the Children’s Health Insurance Program (CHIP) at the level provided under the Affordable Care Act.

 

 

Unfortunately, surgeons will need to become familiar with an entire new lexicon of acronyms associated with this new law and its policy. While this may initially seem daunting and confusing, it can be mastered with relative ease. It is my hope to continue to facilitate such with the content provided herein with the June edition of this column.

Until next month …

Dr. Bailey is a pediatric surgeon and Medical Director, Advocacy for the Division of Advocacy and Health Policy in the ACS offices in Washington, DC.

References

Author and Disclosure Information

Publications
Sections
Author and Disclosure Information

Author and Disclosure Information

S…G…R (continued) – It is much to all of our collective delight and relief that the SGR has finally been relegated to the ash heap of history.

In the late evening of April 14, in an act of historic bipartisanship, the Senate voted 92-8 in favor of H.R. 2 thus completing legislative action about which I wrote last month. President Obama signed the bill into law on April 16. As I write, Dave Hoyt, ACS Executive Director, is attending an event at the White House, along with other leaders of the physician community, to celebrate the full and permanent repeal of the SGR.

Dr. Patrick V. Bailey, FACS

In the coming months, I will use this column to inform surgeons about various components of the legislation and its attendant policy. To start this process, I would first like to cover the key provisions of what is now known as MACRA – the Medicare Access and CHIP Reauthorization Act.

For starters, MACRA fully and permanently repeals the sustainable growth rate (SGR), thus providing stability to the Medicare physician fee schedule. Such repeal averts a 21% SGR-induced cut scheduled for April 1, 2015. MACRA also provides modest but stable positive updates of 0.5%/year for 5 years. When the legislative template that ultimately became MACRA was negotiated in late 2013 and early 2014, no provision was initially made for a positive update to physician payment. However, as a direct result of objections made by the leadership of the ACS, the legislation was subsequently revised to include the 0.5%/year update.

In addition, MACRA provides for the elimination, in 2018, of the current-law penalties associated with the existing quality programs, namely the Physician Quality Reporting System (PQRS), the Value-Based Modifier (VBM) program, and the Electronic Health Record-Meaningful Use (EHR-MU) program. The monies expected from those penalties will be returned to the pool, thus increasing the amount of funds available for incentive updates.

Beginning in 2019, these three programs will be combined into a single program known as the Merit-Based Incentive Payment System (MIPS). The MIPS makes it possible for all surgeons to receive an annual positive update based on their individual performance in four categories of Quality, Resource Use, Meaningful use of the electronic health record, and Clinical practice improvement activities. Surgeons will receive an annual, individual, single composite score based on their performance in these four categories. This score will be compared to a threshold score, defined as either the mean or median of composite scores from a prior performance period. Those with a score above the threshold will receive a positive adjustment and those with a score below the threshold will receive a negative adjustment.The legislation also provides the opportunity to receive a 5% bonus beginning in 2019 for participation in an Alternative Payment Model (APM). Surgeons who meet the full APM criteria will also be excluded from the MIPS assessment and most EHR-MU requirements. Those who participate in an APM at lower levels will receive credit toward their MIPS score. The bonus payment encourages the development of, testing of, and participation in an alternative payment model.

The passage of MACRA also represents a major victory relative to the College’s efforts to rescind the CMS policy transitioning 10- and 90-day global codes to zero-day global codes. ACS leadership and staff of the D.C. office had direct input into the specific language included in the legislation through multiple exchanges with congressional committee staff. In short, MACRA prohibits CMS from implementing its flawed plan relative to the transitioning of the global codes. Instead, beginning no later than 2017, CMS will collect samples of data on the number and level of postoperative visits furnished during the global period. Beginning in 2019, CMS will use this data to improve the accuracy of the valuation of surgical services. CMS is allowed to withhold 5% of the surgical payment until the sample information is reported at the end of the global period.

While MACRA does not implement broad medical liability reforms, it does include a provision which assures that MIPS participation cannot be used in a medical liability action. Specifically, the legislation specifies that the development, recognition or implementation of any guideline or other standard under any federal health care provision, including Medicare, cannot be construed as to establish the standard of care or duty of care owed by a surgeon to a patient in any medical malpractice claim.

Finally, and of particular interest to pediatric surgeons and other surgeons who care for children, MACRA includes two years of additional funding for the Children’s Health Insurance Program (CHIP) at the level provided under the Affordable Care Act.

 

 

Unfortunately, surgeons will need to become familiar with an entire new lexicon of acronyms associated with this new law and its policy. While this may initially seem daunting and confusing, it can be mastered with relative ease. It is my hope to continue to facilitate such with the content provided herein with the June edition of this column.

Until next month …

Dr. Bailey is a pediatric surgeon and Medical Director, Advocacy for the Division of Advocacy and Health Policy in the ACS offices in Washington, DC.

S…G…R (continued) – It is much to all of our collective delight and relief that the SGR has finally been relegated to the ash heap of history.

In the late evening of April 14, in an act of historic bipartisanship, the Senate voted 92-8 in favor of H.R. 2 thus completing legislative action about which I wrote last month. President Obama signed the bill into law on April 16. As I write, Dave Hoyt, ACS Executive Director, is attending an event at the White House, along with other leaders of the physician community, to celebrate the full and permanent repeal of the SGR.

Dr. Patrick V. Bailey, FACS

In the coming months, I will use this column to inform surgeons about various components of the legislation and its attendant policy. To start this process, I would first like to cover the key provisions of what is now known as MACRA – the Medicare Access and CHIP Reauthorization Act.

For starters, MACRA fully and permanently repeals the sustainable growth rate (SGR), thus providing stability to the Medicare physician fee schedule. Such repeal averts a 21% SGR-induced cut scheduled for April 1, 2015. MACRA also provides modest but stable positive updates of 0.5%/year for 5 years. When the legislative template that ultimately became MACRA was negotiated in late 2013 and early 2014, no provision was initially made for a positive update to physician payment. However, as a direct result of objections made by the leadership of the ACS, the legislation was subsequently revised to include the 0.5%/year update.

In addition, MACRA provides for the elimination, in 2018, of the current-law penalties associated with the existing quality programs, namely the Physician Quality Reporting System (PQRS), the Value-Based Modifier (VBM) program, and the Electronic Health Record-Meaningful Use (EHR-MU) program. The monies expected from those penalties will be returned to the pool, thus increasing the amount of funds available for incentive updates.

Beginning in 2019, these three programs will be combined into a single program known as the Merit-Based Incentive Payment System (MIPS). The MIPS makes it possible for all surgeons to receive an annual positive update based on their individual performance in four categories of Quality, Resource Use, Meaningful use of the electronic health record, and Clinical practice improvement activities. Surgeons will receive an annual, individual, single composite score based on their performance in these four categories. This score will be compared to a threshold score, defined as either the mean or median of composite scores from a prior performance period. Those with a score above the threshold will receive a positive adjustment and those with a score below the threshold will receive a negative adjustment.The legislation also provides the opportunity to receive a 5% bonus beginning in 2019 for participation in an Alternative Payment Model (APM). Surgeons who meet the full APM criteria will also be excluded from the MIPS assessment and most EHR-MU requirements. Those who participate in an APM at lower levels will receive credit toward their MIPS score. The bonus payment encourages the development of, testing of, and participation in an alternative payment model.

The passage of MACRA also represents a major victory relative to the College’s efforts to rescind the CMS policy transitioning 10- and 90-day global codes to zero-day global codes. ACS leadership and staff of the D.C. office had direct input into the specific language included in the legislation through multiple exchanges with congressional committee staff. In short, MACRA prohibits CMS from implementing its flawed plan relative to the transitioning of the global codes. Instead, beginning no later than 2017, CMS will collect samples of data on the number and level of postoperative visits furnished during the global period. Beginning in 2019, CMS will use this data to improve the accuracy of the valuation of surgical services. CMS is allowed to withhold 5% of the surgical payment until the sample information is reported at the end of the global period.

While MACRA does not implement broad medical liability reforms, it does include a provision which assures that MIPS participation cannot be used in a medical liability action. Specifically, the legislation specifies that the development, recognition or implementation of any guideline or other standard under any federal health care provision, including Medicare, cannot be construed as to establish the standard of care or duty of care owed by a surgeon to a patient in any medical malpractice claim.

Finally, and of particular interest to pediatric surgeons and other surgeons who care for children, MACRA includes two years of additional funding for the Children’s Health Insurance Program (CHIP) at the level provided under the Affordable Care Act.

 

 

Unfortunately, surgeons will need to become familiar with an entire new lexicon of acronyms associated with this new law and its policy. While this may initially seem daunting and confusing, it can be mastered with relative ease. It is my hope to continue to facilitate such with the content provided herein with the June edition of this column.

Until next month …

Dr. Bailey is a pediatric surgeon and Medical Director, Advocacy for the Division of Advocacy and Health Policy in the ACS offices in Washington, DC.

References

References

Publications
Publications
Article Type
Display Headline
From the Washington Office
Display Headline
From the Washington Office
Sections
Article Source

PURLs Copyright

Inside the Article

Lessons from our dying patients

Article Type
Changed
Wed, 01/02/2019 - 09:13
Display Headline
Lessons from our dying patients

Dying patients teach us to think more carefully about whether or not our surgical interventions will be beneficial.

I work in palliative care, and my surgical colleagues, especially the residents, are often surprised when I call them and ask them to consult on my patients who are very ill and have a “Do Not Resuscitate” order in their charts. I’m also an anesthesiologist working in interventional pain management, and I regularly do procedures on patients who have prognoses that are extremely limited. For other patients, I recommend against any interventions at all.

Dr. Rickerson

How do we know when to intervene on patients who are dying? Perhaps more importantly, how do we know when NOT to intervene? Two recent
cases of almost identical fractures illustrated for me the need to think beyond the anatomic problem when evaluating options for care.

Last year, I admitted a woman, “Donna,” with widely metastatic breast cancer to our inpatient palliative care service. She had fallen at home and hurt her arm about 2 months prior to admission. She had been confined to her bed for about 6 weeks. She was brought to the hospital because she was becoming delirious. She had many sources of pain that were relatively well controlled when she was lying down, but her worst pain was in her left arm. We found a fracture of her humerus. When her family learned that the fracture would not heal on its own because of the large metastasis there, they demanded surgery to fix it. Shortly thereafter, I re-admitted a patient, “Cindy,” with a very similar story. She also had widely metastatic breast cancer, and her pain had been very difficult to control. We had found a pain regimen that worked well for her on her previous admission, but she had fallen over her walker and broke her humerus after we had discharged her to a rehab facility. When I saw her back in the hospital, I told her that I thought she would need surgery to fix her arm. She was depressed by this setback, she was in pain again, and she told me that she would prefer not to have any intervention because she feared the additional pain that it would cause.

With Donna, we sat down with her and her family to hear what their hopes were for her care. They understood that she did not have further chemotherapy or radiation options for her cancer, but they thought if she got the surgery that at least she would be able to get out of bed and walk again. My colleague carefully explained that yes, he could fix the fracture and that this could mean that the pain in her left arm would improve. He went on to say, however, that he did not think that the surgery would allow her to walk again as she had not been able to walk for a few weeks after the injury. When the family heard that the surgery probably wouldn’t restore her mobility, they decided against the procedure. With Cindy, we had a very different conversation. She was not inclined to have the procedure, but I expressed my concern that she wouldn’t be able to walk again unless she had the procedure because she needed her arms to use her walker. Although she did not have any further chemotherapy or radiation options, her oncologist had told us that her prognosis could be several months. In this case, my surgical colleague explained that he could perform surgery for the fracture and that he thought that it would both help her pain and allow her to use her walker again. We recommended that she have the surgery given her hope to continue to live independently, as she had been, for as long as possible. She ultimately agreed to do so and was able to return home.

These two patients reminded me again of how important it is for us to understand what our patients’ hopes and expectations are for a procedure. It is very distressing for clinicians when desperate families want treatments that likely have little benefit. When patients have limited prognoses, aligning patient goals and procedure goals is especially important as the outcome of the procedure can define the patient’s remaining days.

Donna’s family demanded a surgery expecting a result that was very unlikely, and Cindy initially declined the same surgery that ultimately benefitted her greatly. Our job is to make and execute the medical recommendations that best fit with our patients’ goals and understanding. Sometimes this will mean performing procedures on patients who are extremely ill and have “Do Not Resuscitate” orders, and at other times, it will mean not doing procedures, even if a patient and family want them to be done.

 

 

Dr. Rickerson is an anesthesiologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston.


References

Author and Disclosure Information

Publications
Topics
Sections
Author and Disclosure Information

Author and Disclosure Information

Dying patients teach us to think more carefully about whether or not our surgical interventions will be beneficial.

I work in palliative care, and my surgical colleagues, especially the residents, are often surprised when I call them and ask them to consult on my patients who are very ill and have a “Do Not Resuscitate” order in their charts. I’m also an anesthesiologist working in interventional pain management, and I regularly do procedures on patients who have prognoses that are extremely limited. For other patients, I recommend against any interventions at all.

Dr. Rickerson

How do we know when to intervene on patients who are dying? Perhaps more importantly, how do we know when NOT to intervene? Two recent
cases of almost identical fractures illustrated for me the need to think beyond the anatomic problem when evaluating options for care.

Last year, I admitted a woman, “Donna,” with widely metastatic breast cancer to our inpatient palliative care service. She had fallen at home and hurt her arm about 2 months prior to admission. She had been confined to her bed for about 6 weeks. She was brought to the hospital because she was becoming delirious. She had many sources of pain that were relatively well controlled when she was lying down, but her worst pain was in her left arm. We found a fracture of her humerus. When her family learned that the fracture would not heal on its own because of the large metastasis there, they demanded surgery to fix it. Shortly thereafter, I re-admitted a patient, “Cindy,” with a very similar story. She also had widely metastatic breast cancer, and her pain had been very difficult to control. We had found a pain regimen that worked well for her on her previous admission, but she had fallen over her walker and broke her humerus after we had discharged her to a rehab facility. When I saw her back in the hospital, I told her that I thought she would need surgery to fix her arm. She was depressed by this setback, she was in pain again, and she told me that she would prefer not to have any intervention because she feared the additional pain that it would cause.

With Donna, we sat down with her and her family to hear what their hopes were for her care. They understood that she did not have further chemotherapy or radiation options for her cancer, but they thought if she got the surgery that at least she would be able to get out of bed and walk again. My colleague carefully explained that yes, he could fix the fracture and that this could mean that the pain in her left arm would improve. He went on to say, however, that he did not think that the surgery would allow her to walk again as she had not been able to walk for a few weeks after the injury. When the family heard that the surgery probably wouldn’t restore her mobility, they decided against the procedure. With Cindy, we had a very different conversation. She was not inclined to have the procedure, but I expressed my concern that she wouldn’t be able to walk again unless she had the procedure because she needed her arms to use her walker. Although she did not have any further chemotherapy or radiation options, her oncologist had told us that her prognosis could be several months. In this case, my surgical colleague explained that he could perform surgery for the fracture and that he thought that it would both help her pain and allow her to use her walker again. We recommended that she have the surgery given her hope to continue to live independently, as she had been, for as long as possible. She ultimately agreed to do so and was able to return home.

These two patients reminded me again of how important it is for us to understand what our patients’ hopes and expectations are for a procedure. It is very distressing for clinicians when desperate families want treatments that likely have little benefit. When patients have limited prognoses, aligning patient goals and procedure goals is especially important as the outcome of the procedure can define the patient’s remaining days.

Donna’s family demanded a surgery expecting a result that was very unlikely, and Cindy initially declined the same surgery that ultimately benefitted her greatly. Our job is to make and execute the medical recommendations that best fit with our patients’ goals and understanding. Sometimes this will mean performing procedures on patients who are extremely ill and have “Do Not Resuscitate” orders, and at other times, it will mean not doing procedures, even if a patient and family want them to be done.

 

 

Dr. Rickerson is an anesthesiologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston.


Dying patients teach us to think more carefully about whether or not our surgical interventions will be beneficial.

I work in palliative care, and my surgical colleagues, especially the residents, are often surprised when I call them and ask them to consult on my patients who are very ill and have a “Do Not Resuscitate” order in their charts. I’m also an anesthesiologist working in interventional pain management, and I regularly do procedures on patients who have prognoses that are extremely limited. For other patients, I recommend against any interventions at all.

Dr. Rickerson

How do we know when to intervene on patients who are dying? Perhaps more importantly, how do we know when NOT to intervene? Two recent
cases of almost identical fractures illustrated for me the need to think beyond the anatomic problem when evaluating options for care.

Last year, I admitted a woman, “Donna,” with widely metastatic breast cancer to our inpatient palliative care service. She had fallen at home and hurt her arm about 2 months prior to admission. She had been confined to her bed for about 6 weeks. She was brought to the hospital because she was becoming delirious. She had many sources of pain that were relatively well controlled when she was lying down, but her worst pain was in her left arm. We found a fracture of her humerus. When her family learned that the fracture would not heal on its own because of the large metastasis there, they demanded surgery to fix it. Shortly thereafter, I re-admitted a patient, “Cindy,” with a very similar story. She also had widely metastatic breast cancer, and her pain had been very difficult to control. We had found a pain regimen that worked well for her on her previous admission, but she had fallen over her walker and broke her humerus after we had discharged her to a rehab facility. When I saw her back in the hospital, I told her that I thought she would need surgery to fix her arm. She was depressed by this setback, she was in pain again, and she told me that she would prefer not to have any intervention because she feared the additional pain that it would cause.

With Donna, we sat down with her and her family to hear what their hopes were for her care. They understood that she did not have further chemotherapy or radiation options for her cancer, but they thought if she got the surgery that at least she would be able to get out of bed and walk again. My colleague carefully explained that yes, he could fix the fracture and that this could mean that the pain in her left arm would improve. He went on to say, however, that he did not think that the surgery would allow her to walk again as she had not been able to walk for a few weeks after the injury. When the family heard that the surgery probably wouldn’t restore her mobility, they decided against the procedure. With Cindy, we had a very different conversation. She was not inclined to have the procedure, but I expressed my concern that she wouldn’t be able to walk again unless she had the procedure because she needed her arms to use her walker. Although she did not have any further chemotherapy or radiation options, her oncologist had told us that her prognosis could be several months. In this case, my surgical colleague explained that he could perform surgery for the fracture and that he thought that it would both help her pain and allow her to use her walker again. We recommended that she have the surgery given her hope to continue to live independently, as she had been, for as long as possible. She ultimately agreed to do so and was able to return home.

These two patients reminded me again of how important it is for us to understand what our patients’ hopes and expectations are for a procedure. It is very distressing for clinicians when desperate families want treatments that likely have little benefit. When patients have limited prognoses, aligning patient goals and procedure goals is especially important as the outcome of the procedure can define the patient’s remaining days.

Donna’s family demanded a surgery expecting a result that was very unlikely, and Cindy initially declined the same surgery that ultimately benefitted her greatly. Our job is to make and execute the medical recommendations that best fit with our patients’ goals and understanding. Sometimes this will mean performing procedures on patients who are extremely ill and have “Do Not Resuscitate” orders, and at other times, it will mean not doing procedures, even if a patient and family want them to be done.

 

 

Dr. Rickerson is an anesthesiologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston.


References

References

Publications
Publications
Topics
Article Type
Display Headline
Lessons from our dying patients
Display Headline
Lessons from our dying patients
Sections
Article Source

PURLs Copyright

Inside the Article

Avoiding metformin in renal insufficiency

Article Type
Changed
Tue, 05/03/2022 - 15:40
Display Headline
Avoiding metformin in renal insufficiency

A 47-year-old obese male with type 2 diabetes has been on metformin for the last 2 years with good effect (hemoglobin A1c of 6.8), and with exercise has been able to lose 5-10 pounds. His last two blood tests show creatinine levels of 1.5 and 1.6. What do you recommend?

A) Continue with metformin.

B) Stop metformin, start sulfonylurea.

C) Stop metformin, begin glargine.

D) Stop metformin, begin pioglitazone.

Myth: Metformin should not be used in patients with mild to moderate renal insufficiency because of an increased risk of lactic acidosis.

Metformin is the most commonly used oral agent for the treatment of type 2 diabetes in the United States, but the FDA-approved drug label states that it is contraindicated in patients with an abnormal creatinine clearance or serum creatinine of 1.4 in women and 1.5 in men.<sup/>The concern is for development of lactic acidosis in patients because the renally excreted metformin may build up as a result of decreased renal function.

Metformin was approved for use in the United States in 1995, many years after the drug was introduced in Europe. The first drug in its class, phenformin, was removed from the United States and most European markets in 1977 because of a high incidence of lactic acidosis occurring at therapeutic doses. One in 4,000 patients taking phenformin develops lactic acidosis (J. Emerg. Med. 1998;16:881-6). Phenformin has been shown to cause type B lactic acidosis, without evidence of hypoxia or hypoperfusion, and lactic acidosis because of phenformin carried a 50% mortality rate.

Deep concern for the possibility of a similar problem with metformin played an important role in its delay of availability in the United States. It isn’t clear, however, that diabetes patients on metformin have a higher risk of developing lactic acidosis than diabetes patients who are not on metformin.

A Cochrane review of 347 studies, including 70,490 person-years of metformin use, compared with 55,451 person-years in the nonmetformin group, showed no cases of fatal or nonfatal lactic acidosis in either group (Cochrane Database Syst. Rev. 2010 Apr 14:CD002967). More than half the studies included (53%) allowed for the inclusion of patients with creatinine levels greater than 1.5. There were no differences in lactate levels between metformin-treated patients and patients who did not receive metformin.

In a study using the Saskatchewan Health administrative database, which involved 11,797 patients with 22,296 years of metformin exposure, there were two cases of lactic acidosis (Diabetes Care 1999;22:925-7). This calculates to a rate of 9 cases per 100,000 person years, the same rate as in patients with diabetes who are not taking metformin (9.7 cases per 100,000) (Diabetes Care 1998;21:1659-63).

A recent study looked at the incidence of lactic acidosis in patients taking metformin with and without abnormalities in renal function (Diabetes Care 2014;37:2291-5). There was no statistically significant difference in the rates of lactic acidosis in patients who were on metformin with normal renal function, compared with those with varying degrees of renal insufficiency. The overall rate of lactic acidosis was 10.3 per 100,000 patient years, which is almost identical to the rates in the other studies mentioned, and there were no fatalities.

Several recommendations for using metformin in patients with renal insufficiency have been published (see table) (JAMA 2014;312:2668-75; Diabetes Care 2011;34:1431-7). Metformin has shown cardiovascular mortality benefits, compared with sulfonylureas, in the treatment of diabetes (Diabetes Care 2013;36:1304-11). Avoiding its use in patients with mild to moderate renal insufficiency in favor of other treatments that may not be as beneficial and may well lead to worse outcomes.

There is no evidence that metformin increases the lactic acidosis risk in patients with diabetes, but until there is a change in the FDA labeling, physicians will likely continue to be hesitant to use it in patients with renal insufficiency.

Dr. Paauw is professor of medicine in the division of general internal medicine at the University of Washington, Seattle, and he serves as third-year medical student clerkship director at the University of Washington. He is the Rathmann Family Foundation Chair in Patient-Centered Clinical Education. Contact Dr. Paauw at [email protected].

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
diabetes, metformin, renal insufficiency, kidney disease, type 2 diabetes, lactic acidosis
Sections
Author and Disclosure Information

Author and Disclosure Information

A 47-year-old obese male with type 2 diabetes has been on metformin for the last 2 years with good effect (hemoglobin A1c of 6.8), and with exercise has been able to lose 5-10 pounds. His last two blood tests show creatinine levels of 1.5 and 1.6. What do you recommend?

A) Continue with metformin.

B) Stop metformin, start sulfonylurea.

C) Stop metformin, begin glargine.

D) Stop metformin, begin pioglitazone.

Myth: Metformin should not be used in patients with mild to moderate renal insufficiency because of an increased risk of lactic acidosis.

Metformin is the most commonly used oral agent for the treatment of type 2 diabetes in the United States, but the FDA-approved drug label states that it is contraindicated in patients with an abnormal creatinine clearance or serum creatinine of 1.4 in women and 1.5 in men.<sup/>The concern is for development of lactic acidosis in patients because the renally excreted metformin may build up as a result of decreased renal function.

Metformin was approved for use in the United States in 1995, many years after the drug was introduced in Europe. The first drug in its class, phenformin, was removed from the United States and most European markets in 1977 because of a high incidence of lactic acidosis occurring at therapeutic doses. One in 4,000 patients taking phenformin develops lactic acidosis (J. Emerg. Med. 1998;16:881-6). Phenformin has been shown to cause type B lactic acidosis, without evidence of hypoxia or hypoperfusion, and lactic acidosis because of phenformin carried a 50% mortality rate.

Deep concern for the possibility of a similar problem with metformin played an important role in its delay of availability in the United States. It isn’t clear, however, that diabetes patients on metformin have a higher risk of developing lactic acidosis than diabetes patients who are not on metformin.

A Cochrane review of 347 studies, including 70,490 person-years of metformin use, compared with 55,451 person-years in the nonmetformin group, showed no cases of fatal or nonfatal lactic acidosis in either group (Cochrane Database Syst. Rev. 2010 Apr 14:CD002967). More than half the studies included (53%) allowed for the inclusion of patients with creatinine levels greater than 1.5. There were no differences in lactate levels between metformin-treated patients and patients who did not receive metformin.

In a study using the Saskatchewan Health administrative database, which involved 11,797 patients with 22,296 years of metformin exposure, there were two cases of lactic acidosis (Diabetes Care 1999;22:925-7). This calculates to a rate of 9 cases per 100,000 person years, the same rate as in patients with diabetes who are not taking metformin (9.7 cases per 100,000) (Diabetes Care 1998;21:1659-63).

A recent study looked at the incidence of lactic acidosis in patients taking metformin with and without abnormalities in renal function (Diabetes Care 2014;37:2291-5). There was no statistically significant difference in the rates of lactic acidosis in patients who were on metformin with normal renal function, compared with those with varying degrees of renal insufficiency. The overall rate of lactic acidosis was 10.3 per 100,000 patient years, which is almost identical to the rates in the other studies mentioned, and there were no fatalities.

Several recommendations for using metformin in patients with renal insufficiency have been published (see table) (JAMA 2014;312:2668-75; Diabetes Care 2011;34:1431-7). Metformin has shown cardiovascular mortality benefits, compared with sulfonylureas, in the treatment of diabetes (Diabetes Care 2013;36:1304-11). Avoiding its use in patients with mild to moderate renal insufficiency in favor of other treatments that may not be as beneficial and may well lead to worse outcomes.

There is no evidence that metformin increases the lactic acidosis risk in patients with diabetes, but until there is a change in the FDA labeling, physicians will likely continue to be hesitant to use it in patients with renal insufficiency.

Dr. Paauw is professor of medicine in the division of general internal medicine at the University of Washington, Seattle, and he serves as third-year medical student clerkship director at the University of Washington. He is the Rathmann Family Foundation Chair in Patient-Centered Clinical Education. Contact Dr. Paauw at [email protected].

A 47-year-old obese male with type 2 diabetes has been on metformin for the last 2 years with good effect (hemoglobin A1c of 6.8), and with exercise has been able to lose 5-10 pounds. His last two blood tests show creatinine levels of 1.5 and 1.6. What do you recommend?

A) Continue with metformin.

B) Stop metformin, start sulfonylurea.

C) Stop metformin, begin glargine.

D) Stop metformin, begin pioglitazone.

Myth: Metformin should not be used in patients with mild to moderate renal insufficiency because of an increased risk of lactic acidosis.

Metformin is the most commonly used oral agent for the treatment of type 2 diabetes in the United States, but the FDA-approved drug label states that it is contraindicated in patients with an abnormal creatinine clearance or serum creatinine of 1.4 in women and 1.5 in men.<sup/>The concern is for development of lactic acidosis in patients because the renally excreted metformin may build up as a result of decreased renal function.

Metformin was approved for use in the United States in 1995, many years after the drug was introduced in Europe. The first drug in its class, phenformin, was removed from the United States and most European markets in 1977 because of a high incidence of lactic acidosis occurring at therapeutic doses. One in 4,000 patients taking phenformin develops lactic acidosis (J. Emerg. Med. 1998;16:881-6). Phenformin has been shown to cause type B lactic acidosis, without evidence of hypoxia or hypoperfusion, and lactic acidosis because of phenformin carried a 50% mortality rate.

Deep concern for the possibility of a similar problem with metformin played an important role in its delay of availability in the United States. It isn’t clear, however, that diabetes patients on metformin have a higher risk of developing lactic acidosis than diabetes patients who are not on metformin.

A Cochrane review of 347 studies, including 70,490 person-years of metformin use, compared with 55,451 person-years in the nonmetformin group, showed no cases of fatal or nonfatal lactic acidosis in either group (Cochrane Database Syst. Rev. 2010 Apr 14:CD002967). More than half the studies included (53%) allowed for the inclusion of patients with creatinine levels greater than 1.5. There were no differences in lactate levels between metformin-treated patients and patients who did not receive metformin.

In a study using the Saskatchewan Health administrative database, which involved 11,797 patients with 22,296 years of metformin exposure, there were two cases of lactic acidosis (Diabetes Care 1999;22:925-7). This calculates to a rate of 9 cases per 100,000 person years, the same rate as in patients with diabetes who are not taking metformin (9.7 cases per 100,000) (Diabetes Care 1998;21:1659-63).

A recent study looked at the incidence of lactic acidosis in patients taking metformin with and without abnormalities in renal function (Diabetes Care 2014;37:2291-5). There was no statistically significant difference in the rates of lactic acidosis in patients who were on metformin with normal renal function, compared with those with varying degrees of renal insufficiency. The overall rate of lactic acidosis was 10.3 per 100,000 patient years, which is almost identical to the rates in the other studies mentioned, and there were no fatalities.

Several recommendations for using metformin in patients with renal insufficiency have been published (see table) (JAMA 2014;312:2668-75; Diabetes Care 2011;34:1431-7). Metformin has shown cardiovascular mortality benefits, compared with sulfonylureas, in the treatment of diabetes (Diabetes Care 2013;36:1304-11). Avoiding its use in patients with mild to moderate renal insufficiency in favor of other treatments that may not be as beneficial and may well lead to worse outcomes.

There is no evidence that metformin increases the lactic acidosis risk in patients with diabetes, but until there is a change in the FDA labeling, physicians will likely continue to be hesitant to use it in patients with renal insufficiency.

Dr. Paauw is professor of medicine in the division of general internal medicine at the University of Washington, Seattle, and he serves as third-year medical student clerkship director at the University of Washington. He is the Rathmann Family Foundation Chair in Patient-Centered Clinical Education. Contact Dr. Paauw at [email protected].

References

References

Publications
Publications
Topics
Article Type
Display Headline
Avoiding metformin in renal insufficiency
Display Headline
Avoiding metformin in renal insufficiency
Legacy Keywords
diabetes, metformin, renal insufficiency, kidney disease, type 2 diabetes, lactic acidosis
Legacy Keywords
diabetes, metformin, renal insufficiency, kidney disease, type 2 diabetes, lactic acidosis
Sections
Article Source

PURLs Copyright

Inside the Article

Best interest

Article Type
Changed
Fri, 01/18/2019 - 14:47
Display Headline
Best interest

 A dense broth of tedium, a sprinkle of annoyance, and a dash of trepidation – these are the ingredients of the mental soup that simmers in my head when I answer a middle-of-the-night parent phone call.

At least they were until the task of solving the community’s nighttime phone “crises” fell upon the able, eager shoulders of our new interns.

Dr. Shashank P. Behere

Every now and then, the universe throws up a surprise. One night, my intern was placating a very angry man who was upset with his inconsolable baby. He was the foster father of a baby with neonatal abstinence syndrome (NAS) who had been discharged earlier that day.

“I feel like this baby’s been thrown at us! He wasn’t ready to go home!” he cried. Having never met the baby (foster mom had taken the baby home), this man had returned from a long work shift to find a screaming baby at home. He was aggressive and rude as he ranted at my intern. She empathized and explained that other symptoms might include rapid breathing, irritability, sleep problems, etc.

Although she handled the call with consummate grace and professionalism, afterward an uneasy feeling crept over us. An angry, tired man pushed to his limits, and a very difficult, strange new baby at home was a setup for the perfect storm. Our duty in this situation was clear – we were the protectors of this baby’s best interest. That was all that mattered.

With a rising sense of dread, we juggled frantic phone calls between Child Protective Services, the attending physician, the foster family, and the nearest emergency department. All I could think of was how badly we had failed this baby. Something somewhere had gone horribly wrong for this innocent child to be in danger now.

An hour later, when I finally got through to the foster father, he sounded calmer. “We can’t do this,” he stated simply. He informed me he had called Child Protective Services himself. The baby would come back to us temporarily, while we found him a safe home. Relief swept over us.

Perhaps the baby should never have gone home with this family. Perhaps we had no way of knowing this would happen. Perhaps the family did not realize the responsibility they were assuming. We are all only human. We make mistakes. But we pick up the pieces and we try again, guided by the best interest of the children we swear to protect. This desire to keep trying is what makes all the difference in the world. By making the call himself, this man reaffirmed my faith in the process in which we all play a part. May the quest for the best interest of our children endure forever.

Dr. Behere is a third-year resident in pediatrics at Children’s Hospital at Dartmouth-Hitchcock, Lebanon, N.H. E-mail him at [email protected].

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
neonatal abstinence syndrome, baby, best interest, foster parents
Sections
Author and Disclosure Information

Author and Disclosure Information

 A dense broth of tedium, a sprinkle of annoyance, and a dash of trepidation – these are the ingredients of the mental soup that simmers in my head when I answer a middle-of-the-night parent phone call.

At least they were until the task of solving the community’s nighttime phone “crises” fell upon the able, eager shoulders of our new interns.

Dr. Shashank P. Behere

Every now and then, the universe throws up a surprise. One night, my intern was placating a very angry man who was upset with his inconsolable baby. He was the foster father of a baby with neonatal abstinence syndrome (NAS) who had been discharged earlier that day.

“I feel like this baby’s been thrown at us! He wasn’t ready to go home!” he cried. Having never met the baby (foster mom had taken the baby home), this man had returned from a long work shift to find a screaming baby at home. He was aggressive and rude as he ranted at my intern. She empathized and explained that other symptoms might include rapid breathing, irritability, sleep problems, etc.

Although she handled the call with consummate grace and professionalism, afterward an uneasy feeling crept over us. An angry, tired man pushed to his limits, and a very difficult, strange new baby at home was a setup for the perfect storm. Our duty in this situation was clear – we were the protectors of this baby’s best interest. That was all that mattered.

With a rising sense of dread, we juggled frantic phone calls between Child Protective Services, the attending physician, the foster family, and the nearest emergency department. All I could think of was how badly we had failed this baby. Something somewhere had gone horribly wrong for this innocent child to be in danger now.

An hour later, when I finally got through to the foster father, he sounded calmer. “We can’t do this,” he stated simply. He informed me he had called Child Protective Services himself. The baby would come back to us temporarily, while we found him a safe home. Relief swept over us.

Perhaps the baby should never have gone home with this family. Perhaps we had no way of knowing this would happen. Perhaps the family did not realize the responsibility they were assuming. We are all only human. We make mistakes. But we pick up the pieces and we try again, guided by the best interest of the children we swear to protect. This desire to keep trying is what makes all the difference in the world. By making the call himself, this man reaffirmed my faith in the process in which we all play a part. May the quest for the best interest of our children endure forever.

Dr. Behere is a third-year resident in pediatrics at Children’s Hospital at Dartmouth-Hitchcock, Lebanon, N.H. E-mail him at [email protected].

 A dense broth of tedium, a sprinkle of annoyance, and a dash of trepidation – these are the ingredients of the mental soup that simmers in my head when I answer a middle-of-the-night parent phone call.

At least they were until the task of solving the community’s nighttime phone “crises” fell upon the able, eager shoulders of our new interns.

Dr. Shashank P. Behere

Every now and then, the universe throws up a surprise. One night, my intern was placating a very angry man who was upset with his inconsolable baby. He was the foster father of a baby with neonatal abstinence syndrome (NAS) who had been discharged earlier that day.

“I feel like this baby’s been thrown at us! He wasn’t ready to go home!” he cried. Having never met the baby (foster mom had taken the baby home), this man had returned from a long work shift to find a screaming baby at home. He was aggressive and rude as he ranted at my intern. She empathized and explained that other symptoms might include rapid breathing, irritability, sleep problems, etc.

Although she handled the call with consummate grace and professionalism, afterward an uneasy feeling crept over us. An angry, tired man pushed to his limits, and a very difficult, strange new baby at home was a setup for the perfect storm. Our duty in this situation was clear – we were the protectors of this baby’s best interest. That was all that mattered.

With a rising sense of dread, we juggled frantic phone calls between Child Protective Services, the attending physician, the foster family, and the nearest emergency department. All I could think of was how badly we had failed this baby. Something somewhere had gone horribly wrong for this innocent child to be in danger now.

An hour later, when I finally got through to the foster father, he sounded calmer. “We can’t do this,” he stated simply. He informed me he had called Child Protective Services himself. The baby would come back to us temporarily, while we found him a safe home. Relief swept over us.

Perhaps the baby should never have gone home with this family. Perhaps we had no way of knowing this would happen. Perhaps the family did not realize the responsibility they were assuming. We are all only human. We make mistakes. But we pick up the pieces and we try again, guided by the best interest of the children we swear to protect. This desire to keep trying is what makes all the difference in the world. By making the call himself, this man reaffirmed my faith in the process in which we all play a part. May the quest for the best interest of our children endure forever.

Dr. Behere is a third-year resident in pediatrics at Children’s Hospital at Dartmouth-Hitchcock, Lebanon, N.H. E-mail him at [email protected].

References

References

Publications
Publications
Topics
Article Type
Display Headline
Best interest
Display Headline
Best interest
Legacy Keywords
neonatal abstinence syndrome, baby, best interest, foster parents
Legacy Keywords
neonatal abstinence syndrome, baby, best interest, foster parents
Sections
Article Source

PURLs Copyright

Inside the Article

Medicare at 50: Or, the end of fee-for-service

Article Type
Changed
Thu, 03/28/2019 - 15:26
Display Headline
Medicare at 50: Or, the end of fee-for-service

Few of my readers were around when Medicare was signed into law in 1965 by President Lyndon Johnson. Mr. Johnson was into his first elected term as president, having first taken the oath of office with the assassination of John F. Kennedy in November 1963.

Hardly a darling of the liberal left, he was maligned as the perpetrator, if not for the expansion, of the Vietnam War. He was elected with the largest presidential plurality in history, receiving 61% of the votes, and he carried with him a solid Democratic Congress bolstered by a large block of solid Southern Democrats, a firmament from which he had emerged. He can be credited for the most far-reaching social legislation of the 20th century, second only to Franklin Delano Roosevelt of the 1930s. Johnson was able to move the Civil Rights Act of 1964 and the Voting Rights Act and Medicare Act through Congress in 1965, the latter of which we celebrate this year.

Dr. Sidney Goldstein

At the time of passage of Medicare, 35% of Americans over 65 had no health insurance, either because they found insurance unaffordable or because of preexisting illness. Health insurance premiums for the elderly cost roughly three times more than did those for younger individuals. With many of the elderly living on Social Security alone, health insurance was an impossibility. If they needed care, they might find it at the emergency department of their local hospitals.

The battle for the passage of Medicare was formidable. In contrast to the passive role of the American Medical Association in the passage of the Affordable Care Act, Medicare was, to put it mildly, vigorously opposed by most doctors and by the AMA, which viewed it as the harbinger of long-anticipated socialized medicine. It ended up being far from it.

Medicare provided a pathway to an economic bonanza for the practicing physician and to hospitals that they could never have imagined. It immediately expanded the patient population and allowed enterprising and not-so-enterprising doctors and hospitals to run up the costs of health care by strengthening the fee-for-service style of medical care. Doctors, hospitals, and patients had no concern for cost: Medicare paid for everything.

Hospitals found Medicare a ready source of income. Doctor and hospital bills were based on the usual cost to each in their respective communities. Medical educators as well as house staff also saw their income lifted as a result of the federal government’s paying for a large part if not all of the cost of house staff education. Even the small number of physicians who opted out of Medicare, because of the red tape or to preserve their independence from the federal government, benefited. Their fees increased as the payment schedules of Medicare increased in their communities.

One of the by-products of Medicare was the end of hospital segregation. For those of you who were not around then, you can imagine what an impact that had on hospitals and doctors in both the North and the South.

Over time, Medicare expanded its footprint to include treatment of chronic kidney disease at any age, as well as drug coverage. I would guess that most Americans over 65 (this writer included) love Medicare. And doctors? Well, they still grumble about it.

With the recent readjustment of physicians’ Medicare reimbursement rates, the door has been opened to new initiatives based on quality of care. No matter what your political persuasion, it is clear that Americans cannot afford Medicare as we know it. Physicians undoubtedly will find their fee-for-service style of reimbursement curtailed as we learn the definition of “quality care standards.” Quality standards will not only define clinical performance, but will also include cost of rendering that care. So long to the world of fee-for-service reimbursement.

Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.

References

Author and Disclosure Information

Publications
Topics
Sections
Author and Disclosure Information

Author and Disclosure Information

Few of my readers were around when Medicare was signed into law in 1965 by President Lyndon Johnson. Mr. Johnson was into his first elected term as president, having first taken the oath of office with the assassination of John F. Kennedy in November 1963.

Hardly a darling of the liberal left, he was maligned as the perpetrator, if not for the expansion, of the Vietnam War. He was elected with the largest presidential plurality in history, receiving 61% of the votes, and he carried with him a solid Democratic Congress bolstered by a large block of solid Southern Democrats, a firmament from which he had emerged. He can be credited for the most far-reaching social legislation of the 20th century, second only to Franklin Delano Roosevelt of the 1930s. Johnson was able to move the Civil Rights Act of 1964 and the Voting Rights Act and Medicare Act through Congress in 1965, the latter of which we celebrate this year.

Dr. Sidney Goldstein

At the time of passage of Medicare, 35% of Americans over 65 had no health insurance, either because they found insurance unaffordable or because of preexisting illness. Health insurance premiums for the elderly cost roughly three times more than did those for younger individuals. With many of the elderly living on Social Security alone, health insurance was an impossibility. If they needed care, they might find it at the emergency department of their local hospitals.

The battle for the passage of Medicare was formidable. In contrast to the passive role of the American Medical Association in the passage of the Affordable Care Act, Medicare was, to put it mildly, vigorously opposed by most doctors and by the AMA, which viewed it as the harbinger of long-anticipated socialized medicine. It ended up being far from it.

Medicare provided a pathway to an economic bonanza for the practicing physician and to hospitals that they could never have imagined. It immediately expanded the patient population and allowed enterprising and not-so-enterprising doctors and hospitals to run up the costs of health care by strengthening the fee-for-service style of medical care. Doctors, hospitals, and patients had no concern for cost: Medicare paid for everything.

Hospitals found Medicare a ready source of income. Doctor and hospital bills were based on the usual cost to each in their respective communities. Medical educators as well as house staff also saw their income lifted as a result of the federal government’s paying for a large part if not all of the cost of house staff education. Even the small number of physicians who opted out of Medicare, because of the red tape or to preserve their independence from the federal government, benefited. Their fees increased as the payment schedules of Medicare increased in their communities.

One of the by-products of Medicare was the end of hospital segregation. For those of you who were not around then, you can imagine what an impact that had on hospitals and doctors in both the North and the South.

Over time, Medicare expanded its footprint to include treatment of chronic kidney disease at any age, as well as drug coverage. I would guess that most Americans over 65 (this writer included) love Medicare. And doctors? Well, they still grumble about it.

With the recent readjustment of physicians’ Medicare reimbursement rates, the door has been opened to new initiatives based on quality of care. No matter what your political persuasion, it is clear that Americans cannot afford Medicare as we know it. Physicians undoubtedly will find their fee-for-service style of reimbursement curtailed as we learn the definition of “quality care standards.” Quality standards will not only define clinical performance, but will also include cost of rendering that care. So long to the world of fee-for-service reimbursement.

Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.

Few of my readers were around when Medicare was signed into law in 1965 by President Lyndon Johnson. Mr. Johnson was into his first elected term as president, having first taken the oath of office with the assassination of John F. Kennedy in November 1963.

Hardly a darling of the liberal left, he was maligned as the perpetrator, if not for the expansion, of the Vietnam War. He was elected with the largest presidential plurality in history, receiving 61% of the votes, and he carried with him a solid Democratic Congress bolstered by a large block of solid Southern Democrats, a firmament from which he had emerged. He can be credited for the most far-reaching social legislation of the 20th century, second only to Franklin Delano Roosevelt of the 1930s. Johnson was able to move the Civil Rights Act of 1964 and the Voting Rights Act and Medicare Act through Congress in 1965, the latter of which we celebrate this year.

Dr. Sidney Goldstein

At the time of passage of Medicare, 35% of Americans over 65 had no health insurance, either because they found insurance unaffordable or because of preexisting illness. Health insurance premiums for the elderly cost roughly three times more than did those for younger individuals. With many of the elderly living on Social Security alone, health insurance was an impossibility. If they needed care, they might find it at the emergency department of their local hospitals.

The battle for the passage of Medicare was formidable. In contrast to the passive role of the American Medical Association in the passage of the Affordable Care Act, Medicare was, to put it mildly, vigorously opposed by most doctors and by the AMA, which viewed it as the harbinger of long-anticipated socialized medicine. It ended up being far from it.

Medicare provided a pathway to an economic bonanza for the practicing physician and to hospitals that they could never have imagined. It immediately expanded the patient population and allowed enterprising and not-so-enterprising doctors and hospitals to run up the costs of health care by strengthening the fee-for-service style of medical care. Doctors, hospitals, and patients had no concern for cost: Medicare paid for everything.

Hospitals found Medicare a ready source of income. Doctor and hospital bills were based on the usual cost to each in their respective communities. Medical educators as well as house staff also saw their income lifted as a result of the federal government’s paying for a large part if not all of the cost of house staff education. Even the small number of physicians who opted out of Medicare, because of the red tape or to preserve their independence from the federal government, benefited. Their fees increased as the payment schedules of Medicare increased in their communities.

One of the by-products of Medicare was the end of hospital segregation. For those of you who were not around then, you can imagine what an impact that had on hospitals and doctors in both the North and the South.

Over time, Medicare expanded its footprint to include treatment of chronic kidney disease at any age, as well as drug coverage. I would guess that most Americans over 65 (this writer included) love Medicare. And doctors? Well, they still grumble about it.

With the recent readjustment of physicians’ Medicare reimbursement rates, the door has been opened to new initiatives based on quality of care. No matter what your political persuasion, it is clear that Americans cannot afford Medicare as we know it. Physicians undoubtedly will find their fee-for-service style of reimbursement curtailed as we learn the definition of “quality care standards.” Quality standards will not only define clinical performance, but will also include cost of rendering that care. So long to the world of fee-for-service reimbursement.

Dr. Goldstein, medical editor of Cardiology News, is professor of medicine at Wayne State University and division head emeritus of cardiovascular medicine at Henry Ford Hospital, both in Detroit. He is on data safety monitoring committees for the National Institutes of Health and several pharmaceutical companies.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Medicare at 50: Or, the end of fee-for-service
Display Headline
Medicare at 50: Or, the end of fee-for-service
Sections
Article Source

PURLs Copyright

Inside the Article

ACP: The Beantown Airing of Grievances

Article Type
Changed
Thu, 03/28/2019 - 15:27
Display Headline
ACP: The Beantown Airing of Grievances

BOSTON – Four-thirty in the afternoon isn’t the time slot most conference presenters covet.

By that point, many attendees are done for the day – loaded up with new knowledge and weighed down with schwag-stuffed tote bags. By 4:30 p.m., the hotel bar is enjoying stronger attendance and better survey-sheet ratings than a closing-time clinical diagnosis session.

But, by 4:30 Thursday at the annual meeting of the American College of Physicians, cavernous room 107 in Boston’s convention center was filling up.

Was it hosting “Atrial Fibrillation 2015”? “Prescribing Chronic Opioids”? “Update in Endocrinology”?

In fact, the session’s topic wasn’t clinical, but its nature was definitely acute. Room 107’s attendees had arrived for a session with the potential for as much action as the weekend’s upcoming Mayweather-Pacquiao megafight: “ABIM: Understanding MOC Requirements.”

There behind the podium stood the subdued president and CEO of the American Board of Internal Medicine, Dr. Richard J. Baron, looking like a Yankees fan about to lecture the Fenway Park faithful on the many merits of Bucky “Bleepin’ ” Dent.

In fact, before him seethed bleachers of angry doctors eager to share their opinions about what they viewed as ABIM’s own Bucky Dent: the Maintenance of Certification program.

With the ABIM board’s chair-elect, Dr. Clarence Braddock III, sitting nearby on the dais, Dr. Baron dutifully outlined the MOC backtracking that came with February’s public apology by ABIM: updates to its internal medicine exam; suspension of the practice assessment, patient voice, and patient safety requirements for at least 2 years; and MOC enrollment fees set at or below the 2014 levels through at least 2017. And if those three requirements did return, ABIM would give physicians a year’s notice before they would have to start meeting them.

By the end of the year, ABIM also will unveil more flexible ways to earn MOC points, Dr. Baron noted. He also offered his listeners assurances that the fall 2015 MOC exam would better reflect doctors’ clinical experiences.

“The most important thing we learned from Feb. 3 is that ABIM needed to change to an organization much more rooted in the community,” Dr. Baron explained.

Then he opened the meeting to questions from the audience – triggering an Airing of Grievances worthy of a “Seinfeld” Festivus.

Terry Rudd/Frontline Medical Communications
Physicians share their concerns.

Beginning with a New Jersey physician who vigorously aired her own grievances at a volume that made a microphone redundant – “Don’t scare us away – we WANT to keep up!” – room 107’s open mics amplified a steady stream of physicians eager to vent their MOC-fueled fury and despair.

What about changing the MOC exam to open-book? “ ‘Consult the gastroenterologist’ is the real-world approach to solving problems!” Why can’t multiple sources of CME credit count toward MOC? Why not dump the recertification exam and simply use the modules to keep physicians fresh?

One physician who spent most of his practice in urgent-care settings and occupational medicine – in which relationships with patients are, by nature, short-lived – worried that a return of the patient voice requirement would make failure certain for him.

“I may be 72, but I will retire before I do one of those Practice Improvement Modules again!” warned another physician.

Attendees also zeroed in on financial allegations made in two recent Newsweek articles about ABIM (“The Ugly Civil War in American Medicine” and “A Certified Medical Controversy”). “Is an independent group going to review reports about ABIM’s finances?” one attendee asked. Another stated that ABIM’s board shouldn’t be paid, a suggestion for which the doctor received a generous round of applause.

Dr. Baron categorically dismissed claims that ABIM was financially troubled and that it manipulated exams to drive down pass rates – and thus boost its revenues with retests. “We had the sixth-largest auditor review our finances, and they found no issue with our finances,” Dr. Baron countered. “Our audited finances are available on our website.”

Although the audience appeared unified in its deep displeasure with ABIM’s approach to the now-postponed MOC changes, the still-active issue of recertification exams revealed fissures between older and younger doctors.

One younger physician questioned the fairness of the dual system: “Why do older doctors not have to recertify? Abolish grandfathering!”

That drove “grandfathered” physicians to the room mics to defend their exclusion from recertification tests. Some stated that no data backed the belief that recertified physicians delivered better care. One grandfathered physician insisted she shouldn’t be “bullied into recertifying.”

Dr. Baron backed recertification by declaring that “we know that knowledge decays over time.” A study of grandfathered physicians vs. recertified physicians showed higher costs associated with grandfathers, he added.

 

 

After nearly an hour of open mics and talk therapy, the session came to a less-animated end. Attendees drifted off to evening events and, no doubt, nearby hotel bars for postgame MOC analysis. Dr. Baron left with the look of a New York fan relieved simply to escape Fenway Park physically unscathed after a Yankees win.

Will the communal catharsis from the Beantown Airing of Grievances – and similar sessions elsewhere – earn ABIM more time to morph MOC into something more acceptable and relevant to its test-takers and fee-payers before more physicians flee to upstart competing boards? Probably for many physicians, for whom ABIM’s MOC program remains at best a valued, necessary credential, and at worst a necessary evil.

But others say they’ve had enough.

As one physician emphatically declared to her colleagues in room 107 and beyond: “I would like the opportunity to put ‘Boycotting the MOC’ as my status on the ABIM website!”

[email protected]

References

Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
ABIM, MOC, maintenance of certification, American Board of Internal Medicine
Sections
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

BOSTON – Four-thirty in the afternoon isn’t the time slot most conference presenters covet.

By that point, many attendees are done for the day – loaded up with new knowledge and weighed down with schwag-stuffed tote bags. By 4:30 p.m., the hotel bar is enjoying stronger attendance and better survey-sheet ratings than a closing-time clinical diagnosis session.

But, by 4:30 Thursday at the annual meeting of the American College of Physicians, cavernous room 107 in Boston’s convention center was filling up.

Was it hosting “Atrial Fibrillation 2015”? “Prescribing Chronic Opioids”? “Update in Endocrinology”?

In fact, the session’s topic wasn’t clinical, but its nature was definitely acute. Room 107’s attendees had arrived for a session with the potential for as much action as the weekend’s upcoming Mayweather-Pacquiao megafight: “ABIM: Understanding MOC Requirements.”

There behind the podium stood the subdued president and CEO of the American Board of Internal Medicine, Dr. Richard J. Baron, looking like a Yankees fan about to lecture the Fenway Park faithful on the many merits of Bucky “Bleepin’ ” Dent.

In fact, before him seethed bleachers of angry doctors eager to share their opinions about what they viewed as ABIM’s own Bucky Dent: the Maintenance of Certification program.

With the ABIM board’s chair-elect, Dr. Clarence Braddock III, sitting nearby on the dais, Dr. Baron dutifully outlined the MOC backtracking that came with February’s public apology by ABIM: updates to its internal medicine exam; suspension of the practice assessment, patient voice, and patient safety requirements for at least 2 years; and MOC enrollment fees set at or below the 2014 levels through at least 2017. And if those three requirements did return, ABIM would give physicians a year’s notice before they would have to start meeting them.

By the end of the year, ABIM also will unveil more flexible ways to earn MOC points, Dr. Baron noted. He also offered his listeners assurances that the fall 2015 MOC exam would better reflect doctors’ clinical experiences.

“The most important thing we learned from Feb. 3 is that ABIM needed to change to an organization much more rooted in the community,” Dr. Baron explained.

Then he opened the meeting to questions from the audience – triggering an Airing of Grievances worthy of a “Seinfeld” Festivus.

Terry Rudd/Frontline Medical Communications
Physicians share their concerns.

Beginning with a New Jersey physician who vigorously aired her own grievances at a volume that made a microphone redundant – “Don’t scare us away – we WANT to keep up!” – room 107’s open mics amplified a steady stream of physicians eager to vent their MOC-fueled fury and despair.

What about changing the MOC exam to open-book? “ ‘Consult the gastroenterologist’ is the real-world approach to solving problems!” Why can’t multiple sources of CME credit count toward MOC? Why not dump the recertification exam and simply use the modules to keep physicians fresh?

One physician who spent most of his practice in urgent-care settings and occupational medicine – in which relationships with patients are, by nature, short-lived – worried that a return of the patient voice requirement would make failure certain for him.

“I may be 72, but I will retire before I do one of those Practice Improvement Modules again!” warned another physician.

Attendees also zeroed in on financial allegations made in two recent Newsweek articles about ABIM (“The Ugly Civil War in American Medicine” and “A Certified Medical Controversy”). “Is an independent group going to review reports about ABIM’s finances?” one attendee asked. Another stated that ABIM’s board shouldn’t be paid, a suggestion for which the doctor received a generous round of applause.

Dr. Baron categorically dismissed claims that ABIM was financially troubled and that it manipulated exams to drive down pass rates – and thus boost its revenues with retests. “We had the sixth-largest auditor review our finances, and they found no issue with our finances,” Dr. Baron countered. “Our audited finances are available on our website.”

Although the audience appeared unified in its deep displeasure with ABIM’s approach to the now-postponed MOC changes, the still-active issue of recertification exams revealed fissures between older and younger doctors.

One younger physician questioned the fairness of the dual system: “Why do older doctors not have to recertify? Abolish grandfathering!”

That drove “grandfathered” physicians to the room mics to defend their exclusion from recertification tests. Some stated that no data backed the belief that recertified physicians delivered better care. One grandfathered physician insisted she shouldn’t be “bullied into recertifying.”

Dr. Baron backed recertification by declaring that “we know that knowledge decays over time.” A study of grandfathered physicians vs. recertified physicians showed higher costs associated with grandfathers, he added.

 

 

After nearly an hour of open mics and talk therapy, the session came to a less-animated end. Attendees drifted off to evening events and, no doubt, nearby hotel bars for postgame MOC analysis. Dr. Baron left with the look of a New York fan relieved simply to escape Fenway Park physically unscathed after a Yankees win.

Will the communal catharsis from the Beantown Airing of Grievances – and similar sessions elsewhere – earn ABIM more time to morph MOC into something more acceptable and relevant to its test-takers and fee-payers before more physicians flee to upstart competing boards? Probably for many physicians, for whom ABIM’s MOC program remains at best a valued, necessary credential, and at worst a necessary evil.

But others say they’ve had enough.

As one physician emphatically declared to her colleagues in room 107 and beyond: “I would like the opportunity to put ‘Boycotting the MOC’ as my status on the ABIM website!”

[email protected]

BOSTON – Four-thirty in the afternoon isn’t the time slot most conference presenters covet.

By that point, many attendees are done for the day – loaded up with new knowledge and weighed down with schwag-stuffed tote bags. By 4:30 p.m., the hotel bar is enjoying stronger attendance and better survey-sheet ratings than a closing-time clinical diagnosis session.

But, by 4:30 Thursday at the annual meeting of the American College of Physicians, cavernous room 107 in Boston’s convention center was filling up.

Was it hosting “Atrial Fibrillation 2015”? “Prescribing Chronic Opioids”? “Update in Endocrinology”?

In fact, the session’s topic wasn’t clinical, but its nature was definitely acute. Room 107’s attendees had arrived for a session with the potential for as much action as the weekend’s upcoming Mayweather-Pacquiao megafight: “ABIM: Understanding MOC Requirements.”

There behind the podium stood the subdued president and CEO of the American Board of Internal Medicine, Dr. Richard J. Baron, looking like a Yankees fan about to lecture the Fenway Park faithful on the many merits of Bucky “Bleepin’ ” Dent.

In fact, before him seethed bleachers of angry doctors eager to share their opinions about what they viewed as ABIM’s own Bucky Dent: the Maintenance of Certification program.

With the ABIM board’s chair-elect, Dr. Clarence Braddock III, sitting nearby on the dais, Dr. Baron dutifully outlined the MOC backtracking that came with February’s public apology by ABIM: updates to its internal medicine exam; suspension of the practice assessment, patient voice, and patient safety requirements for at least 2 years; and MOC enrollment fees set at or below the 2014 levels through at least 2017. And if those three requirements did return, ABIM would give physicians a year’s notice before they would have to start meeting them.

By the end of the year, ABIM also will unveil more flexible ways to earn MOC points, Dr. Baron noted. He also offered his listeners assurances that the fall 2015 MOC exam would better reflect doctors’ clinical experiences.

“The most important thing we learned from Feb. 3 is that ABIM needed to change to an organization much more rooted in the community,” Dr. Baron explained.

Then he opened the meeting to questions from the audience – triggering an Airing of Grievances worthy of a “Seinfeld” Festivus.

Terry Rudd/Frontline Medical Communications
Physicians share their concerns.

Beginning with a New Jersey physician who vigorously aired her own grievances at a volume that made a microphone redundant – “Don’t scare us away – we WANT to keep up!” – room 107’s open mics amplified a steady stream of physicians eager to vent their MOC-fueled fury and despair.

What about changing the MOC exam to open-book? “ ‘Consult the gastroenterologist’ is the real-world approach to solving problems!” Why can’t multiple sources of CME credit count toward MOC? Why not dump the recertification exam and simply use the modules to keep physicians fresh?

One physician who spent most of his practice in urgent-care settings and occupational medicine – in which relationships with patients are, by nature, short-lived – worried that a return of the patient voice requirement would make failure certain for him.

“I may be 72, but I will retire before I do one of those Practice Improvement Modules again!” warned another physician.

Attendees also zeroed in on financial allegations made in two recent Newsweek articles about ABIM (“The Ugly Civil War in American Medicine” and “A Certified Medical Controversy”). “Is an independent group going to review reports about ABIM’s finances?” one attendee asked. Another stated that ABIM’s board shouldn’t be paid, a suggestion for which the doctor received a generous round of applause.

Dr. Baron categorically dismissed claims that ABIM was financially troubled and that it manipulated exams to drive down pass rates – and thus boost its revenues with retests. “We had the sixth-largest auditor review our finances, and they found no issue with our finances,” Dr. Baron countered. “Our audited finances are available on our website.”

Although the audience appeared unified in its deep displeasure with ABIM’s approach to the now-postponed MOC changes, the still-active issue of recertification exams revealed fissures between older and younger doctors.

One younger physician questioned the fairness of the dual system: “Why do older doctors not have to recertify? Abolish grandfathering!”

That drove “grandfathered” physicians to the room mics to defend their exclusion from recertification tests. Some stated that no data backed the belief that recertified physicians delivered better care. One grandfathered physician insisted she shouldn’t be “bullied into recertifying.”

Dr. Baron backed recertification by declaring that “we know that knowledge decays over time.” A study of grandfathered physicians vs. recertified physicians showed higher costs associated with grandfathers, he added.

 

 

After nearly an hour of open mics and talk therapy, the session came to a less-animated end. Attendees drifted off to evening events and, no doubt, nearby hotel bars for postgame MOC analysis. Dr. Baron left with the look of a New York fan relieved simply to escape Fenway Park physically unscathed after a Yankees win.

Will the communal catharsis from the Beantown Airing of Grievances – and similar sessions elsewhere – earn ABIM more time to morph MOC into something more acceptable and relevant to its test-takers and fee-payers before more physicians flee to upstart competing boards? Probably for many physicians, for whom ABIM’s MOC program remains at best a valued, necessary credential, and at worst a necessary evil.

But others say they’ve had enough.

As one physician emphatically declared to her colleagues in room 107 and beyond: “I would like the opportunity to put ‘Boycotting the MOC’ as my status on the ABIM website!”

[email protected]

References

References

Publications
Publications
Topics
Article Type
Display Headline
ACP: The Beantown Airing of Grievances
Display Headline
ACP: The Beantown Airing of Grievances
Legacy Keywords
ABIM, MOC, maintenance of certification, American Board of Internal Medicine
Legacy Keywords
ABIM, MOC, maintenance of certification, American Board of Internal Medicine
Sections
Article Source

AT ACP INTERNAL MEDICINE 2015

PURLs Copyright

Inside the Article

Prepping for the Boards? We can help

Article Type
Changed
Thu, 03/28/2019 - 15:27
Display Headline
Prepping for the Boards? We can help

The results of the 2015 National Residency Match Program were announced on March 20. For family medicine, the glass was either half empty or half full, depending on your point of view.

On the plus side, 84 more family medicine positions were offered compared to 2014 (3216 vs 3132) and 60 more positions were filled, for a total of 3060 new family medicine residents in 2015.1 This was far more than matched in gloomy 2009, when only 2555 residents chose family medicine. On the negative side of the balance sheet, there will be 233 fewer family medicine residents this year than matched at the peak of medical student interest in family medicine in 1998.

I’m a glass half full kind of guy, so I am delighted that the trend of increased medical student interest in family medicine continues. According to Merritt Hawkins, a national recruitment firm, family medicine has been the top recruited specialty for several years. The firm reports that starting salaries for family physicians increased by nearly 12% from 2010/11 to 2013/14, which was a higher rate than that of most other specialties.2 So there is reason to be optimistic about the future of our specialty.

Our monthly 5-question online quiz can help residents study for their certification exam.

However, to be card-carrying family physicians, our new residents must take the American Board of Family Medicine certification exam, and not all pass on their first attempt. A 2013 study of family medicine residency graduates found that only 86% of graduates passed the board exam on their first try.3

We can help. In addition to the evidence-based reviews published in The Journal of Family Practice (JFP), we have launched a new feature called Residents’ Rapid Review (RRR) to provide an additional resource for residents.

RRR is a monthly 5-question evidence-based quiz prepared by primary care faculty, including current and former residency program directors. After residents click on their answer, the system lets them know whether they’re right and provides the correct answer with an explanation and references. Monthly notifications are sent out to all jfponline.com registered users alerting them that a new quiz is available. (Not a registered user on the site? Sign up at jfponline.com/residents_reg.)

Getting ready for the recertification exam? The RRR quizzes can help you, too. Check out the latest quiz, today!

References

1. National Resident Matching Program. Advance data tables. 2015 main residency match. National Resident Matching Program Web site. Available at: http://www.nrmp.org/wp-content/uploads/2015/03/ADT2015_final.pdf. Accessed April 16, 2015.

2. Merritt Hawkins. 2014 review of physician and advanced practitioner recruiting incentives. Irving, TX: Merritt Hawkins; 2014:9.

3. Falcone JL, Middleton DB. Pass rates on the American Board of Family Medicine Certification Exam by residency location and size. J Am Board Fam Med. 2013;26:453-459.

Article PDF
Author and Disclosure Information

John Hickner, MD, MSc
Editor-in-Chief

Issue
The Journal of Family Practice - 64(5)
Publications
Topics
Page Number
272
Legacy Keywords
John Hickner, MD, MSc; board recertification; residents; Residents' Rapid Review
Sections
Author and Disclosure Information

John Hickner, MD, MSc
Editor-in-Chief

Author and Disclosure Information

John Hickner, MD, MSc
Editor-in-Chief

Article PDF
Article PDF

The results of the 2015 National Residency Match Program were announced on March 20. For family medicine, the glass was either half empty or half full, depending on your point of view.

On the plus side, 84 more family medicine positions were offered compared to 2014 (3216 vs 3132) and 60 more positions were filled, for a total of 3060 new family medicine residents in 2015.1 This was far more than matched in gloomy 2009, when only 2555 residents chose family medicine. On the negative side of the balance sheet, there will be 233 fewer family medicine residents this year than matched at the peak of medical student interest in family medicine in 1998.

I’m a glass half full kind of guy, so I am delighted that the trend of increased medical student interest in family medicine continues. According to Merritt Hawkins, a national recruitment firm, family medicine has been the top recruited specialty for several years. The firm reports that starting salaries for family physicians increased by nearly 12% from 2010/11 to 2013/14, which was a higher rate than that of most other specialties.2 So there is reason to be optimistic about the future of our specialty.

Our monthly 5-question online quiz can help residents study for their certification exam.

However, to be card-carrying family physicians, our new residents must take the American Board of Family Medicine certification exam, and not all pass on their first attempt. A 2013 study of family medicine residency graduates found that only 86% of graduates passed the board exam on their first try.3

We can help. In addition to the evidence-based reviews published in The Journal of Family Practice (JFP), we have launched a new feature called Residents’ Rapid Review (RRR) to provide an additional resource for residents.

RRR is a monthly 5-question evidence-based quiz prepared by primary care faculty, including current and former residency program directors. After residents click on their answer, the system lets them know whether they’re right and provides the correct answer with an explanation and references. Monthly notifications are sent out to all jfponline.com registered users alerting them that a new quiz is available. (Not a registered user on the site? Sign up at jfponline.com/residents_reg.)

Getting ready for the recertification exam? The RRR quizzes can help you, too. Check out the latest quiz, today!

The results of the 2015 National Residency Match Program were announced on March 20. For family medicine, the glass was either half empty or half full, depending on your point of view.

On the plus side, 84 more family medicine positions were offered compared to 2014 (3216 vs 3132) and 60 more positions were filled, for a total of 3060 new family medicine residents in 2015.1 This was far more than matched in gloomy 2009, when only 2555 residents chose family medicine. On the negative side of the balance sheet, there will be 233 fewer family medicine residents this year than matched at the peak of medical student interest in family medicine in 1998.

I’m a glass half full kind of guy, so I am delighted that the trend of increased medical student interest in family medicine continues. According to Merritt Hawkins, a national recruitment firm, family medicine has been the top recruited specialty for several years. The firm reports that starting salaries for family physicians increased by nearly 12% from 2010/11 to 2013/14, which was a higher rate than that of most other specialties.2 So there is reason to be optimistic about the future of our specialty.

Our monthly 5-question online quiz can help residents study for their certification exam.

However, to be card-carrying family physicians, our new residents must take the American Board of Family Medicine certification exam, and not all pass on their first attempt. A 2013 study of family medicine residency graduates found that only 86% of graduates passed the board exam on their first try.3

We can help. In addition to the evidence-based reviews published in The Journal of Family Practice (JFP), we have launched a new feature called Residents’ Rapid Review (RRR) to provide an additional resource for residents.

RRR is a monthly 5-question evidence-based quiz prepared by primary care faculty, including current and former residency program directors. After residents click on their answer, the system lets them know whether they’re right and provides the correct answer with an explanation and references. Monthly notifications are sent out to all jfponline.com registered users alerting them that a new quiz is available. (Not a registered user on the site? Sign up at jfponline.com/residents_reg.)

Getting ready for the recertification exam? The RRR quizzes can help you, too. Check out the latest quiz, today!

References

1. National Resident Matching Program. Advance data tables. 2015 main residency match. National Resident Matching Program Web site. Available at: http://www.nrmp.org/wp-content/uploads/2015/03/ADT2015_final.pdf. Accessed April 16, 2015.

2. Merritt Hawkins. 2014 review of physician and advanced practitioner recruiting incentives. Irving, TX: Merritt Hawkins; 2014:9.

3. Falcone JL, Middleton DB. Pass rates on the American Board of Family Medicine Certification Exam by residency location and size. J Am Board Fam Med. 2013;26:453-459.

References

1. National Resident Matching Program. Advance data tables. 2015 main residency match. National Resident Matching Program Web site. Available at: http://www.nrmp.org/wp-content/uploads/2015/03/ADT2015_final.pdf. Accessed April 16, 2015.

2. Merritt Hawkins. 2014 review of physician and advanced practitioner recruiting incentives. Irving, TX: Merritt Hawkins; 2014:9.

3. Falcone JL, Middleton DB. Pass rates on the American Board of Family Medicine Certification Exam by residency location and size. J Am Board Fam Med. 2013;26:453-459.

Issue
The Journal of Family Practice - 64(5)
Issue
The Journal of Family Practice - 64(5)
Page Number
272
Page Number
272
Publications
Publications
Topics
Article Type
Display Headline
Prepping for the Boards? We can help
Display Headline
Prepping for the Boards? We can help
Legacy Keywords
John Hickner, MD, MSc; board recertification; residents; Residents' Rapid Review
Legacy Keywords
John Hickner, MD, MSc; board recertification; residents; Residents' Rapid Review
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media